<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Azenta, Inc. (AZTA) Q4 2025 Earnings Call November 21, 2025 8:30 AM EST<br><br>Company Participants<br><br>Yvonne Perron - Vice President of Financial Planning & Analysis and Investor Relations<br>John P.</td><td># Azenta, Inc. (AZTA) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ<br><br>**2025ë…„ 11ì›” 21ì¼ ì˜¤ì „ 8ì‹œ 30ë¶„ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)**<br><br>## íšŒì‚¬ ì°¸ì„ì<br><br>**Yvonne Perron** - ì¬ë¬´ê¸°íš ë° ë¶„ì„ ë° íˆ¬ìì ê´€ê³„ ë¶€ì‚¬ì¥<br>**John P.**<br><br>---<br><br>*[ì°¸ê³ : ì œê³µëœ í…ìŠ¤íŠ¸ê°€ ì—¬ê¸°ì„œ ì¤‘ë‹¨ë˜ì—ˆìŠµë‹ˆë‹¤. ì „ì²´ ì‹¤ì  ë°œí‘œ ë‚´ìš©ì„ ì œê³µí•´ ì£¼ì‹œë©´ ì™„ì „í•œ ë²ˆì—­ì„ ì œê³µí•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.]*<br><br>---<br><br>**ë²ˆì—­ ì°¸ê³ ì‚¬í•­:**<br>- íšŒì‚¬ëª… "Azenta, Inc."ì™€ í‹°ì»¤ ì‹¬ë³¼ "(AZTA)"ëŠ” ì›ë¬¸ ê·¸ëŒ€ë¡œ ìœ ì§€í–ˆìŠµë‹ˆë‹¤.<br>- ì§í•¨ê³¼ ë¶€ì„œëª…ì€ í•œêµ­ ê¸°ì—… ê´€í–‰ì— ë§ê²Œ ë²ˆì—­í–ˆìŠµë‹ˆë‹¤.<br>- ì‹œê°„ëŒ€ "EST (Eastern Standard Time)"ëŠ” "ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ"ë¡œ ë²ˆì—­í–ˆìŠµë‹ˆë‹¤.<br>- ì „ë¬¸ì ì´ê³  ìì—°ìŠ¤ëŸ¬ìš´ í•œêµ­ì–´ í‘œí˜„ì„ ì‚¬ìš©í–ˆìŠµë‹ˆë‹¤.<br><br>ì „ì²´ ì»¨í¼ëŸ°ìŠ¤ ì½œ ë‚´ìš©ì„ ì œê³µí•´ ì£¼ì‹œë©´, ì¬ë¬´ ìš©ì–´ì™€ ìˆ˜ì¹˜ë¥¼ ì •í™•íˆ ìœ ì§€í•˜ë©´ì„œ í™”ìì˜ ì–´ì¡°ë¥¼ ì‚´ë¦° ì™„ì „í•œ ë²ˆì—­ì„ ì œê³µí•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Marotta - President, CEO & Director<br>Lawrence Lin - Executive VP & CFO<br><br>Conference Call Participants<br><br>David Saxon - Needham & Company, LLC, Research Division<br>Steven Etoch - Stephens Inc., Research Division<br>Andrew Cooper - Raymond James & Associates, Inc., Research Division<br>Vijay Kumar - Evercore ISI Institutional Equities, Research Division<br>Jacqueline Kisa - TD Cowen, Research Division<br>Paul Knight - KeyBanc Capital Markets Inc., Research Division<br><br>Presentation<br><br>Operator<br><br>Greetings, and welcome to the Azenta Q4 2025 Financial Results. [Operator Instructions] As a reminder, this conference is being recorded Friday, November 21, 2025.</td><td># ì•„ì  íƒ€ 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ<br><br>## ë°œí‘œì<br><br>ë§ˆë¡œíƒ€ - ì‚¬ì¥, CEO ê²¸ ì´ì‚¬<br>ë¡œë ŒìŠ¤ ë¦° - ì „ë¬´ì´ì‚¬ ê²¸ CFO<br><br>## ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>ë°ì´ë¹„ë“œ ìƒ‰ìŠ¨ - ë‹ˆë¤ ì•¤ ì»´í¼ë‹ˆ, LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ìŠ¤í‹°ë¸ ì—í† í¬ - ìŠ¤í‹°ë¸ìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ì•¤ë“œë¥˜ ì¿ í¼ - ë ˆì´ë¨¼ë“œ ì œì„ìŠ¤ ì•¤ ì–´ì†Œì‹œì—ì´ì¸ , ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë¹„ì œì´ ì¿ ë§ˆë¥´ - ì—ë²„ì½”ì–´ ISI ê¸°ê´€íˆ¬ìê°€ ì£¼ì‹ ë¶€ë¬¸<br>ì¬í´ë¦° í‚¤ì‚¬ - TD ì½”ì›¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>í´ ë‚˜ì´íŠ¸ - í‚¤ë±…í¬ ìºí”¼íƒˆ ë§ˆì¼“ì¸ , ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>## ë°œí‘œ<br><br>ì‚¬íšŒì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, ì•„ì  íƒ€ 2025ë…„ 4ë¶„ê¸° ì¬ë¬´ ì‹¤ì  ë°œí‘œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´ì‚¬í•­] ë³¸ ì»¨í¼ëŸ°ìŠ¤ëŠ” 2025ë…„ 11ì›” 21ì¼ ê¸ˆìš”ì¼ì— ë…¹ìŒë˜ê³  ìˆìŒì„ ì•Œë ¤ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>I will now turn the conference over to Yvonne Perron, Vice President, FP&A and Investor Relations. Yvonne Perron<br>Vice President of Financial Planning & Analysis and Investor Relations<br><br>Thank you, operator, and good morning to everyone on the line today. We would like to welcome you to our earnings conference call for the fourth quarter of fiscal year 2025. Our fourth quarter earnings press release was issued before the open of the market today, and is available on our Investor Relations website located at investors.azenta.com in addition to the supplementary PowerPoint slides that will be used during the prepared remarks today.</td><td>ì»¨í¼ëŸ°ìŠ¤ë¥¼ ì´ë³¸ í˜ë¡ (Yvonne Perron) ë¶€ì‚¬ì¥, FP&A ë° íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ì´ë³¸ í˜ë¡ <br>ì¬ë¬´ê¸°íš ë° ë¶„ì„, íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ë¶€ì‚¬ì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ì˜¤í¼ë ˆì´í„°ë‹˜. ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ì „í™”ì— ì°¸ì—¬í•˜ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. 2025 íšŒê³„ì—°ë„ 4ë¶„ê¸° ì‹¤ì  ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ 4ë¶„ê¸° ì‹¤ì  ë³´ë„ìë£ŒëŠ” ì˜¤ëŠ˜ ì¥ ê°œì‹œ ì „ì— ë°œí‘œë˜ì—ˆìœ¼ë©°, investors.azenta.comì— ìœ„ì¹˜í•œ íˆ¬ìì ê´€ê³„ ì›¹ì‚¬ì´íŠ¸ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì˜¤ëŠ˜ ë°œí‘œ ì¤‘ ì‚¬ìš©ë  ë³´ì¶© íŒŒì›Œí¬ì¸íŠ¸ ìŠ¬ë¼ì´ë“œë„ í•¨ê»˜ ì œê³µë©ë‹ˆë‹¤.</td></tr>
<tr><td>Please note that effective the first fiscal quarter of 2025, the results of B Medical Systems are treated as discontinued operations. I would like to remind everyone that during the course of the call, we will be making a number of forward-looking statements within the meaning of the Private Litigation Securities Act of 1995. There are many factors that may cause actual financial results or other events to differ from those identified in such forward-looking statements.</td><td>ì£¼ì˜í•˜ì‹¤ ì ì€ 2025 íšŒê³„ì—°ë„ 1ë¶„ê¸°ë¶€í„° B Medical Systemsì˜ ì‹¤ì ì´ ì¤‘ë‹¨ ì‚¬ì—…ìœ¼ë¡œ ì²˜ë¦¬ëœë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. í†µí™” ì¤‘ì— 1995ë…„ ì¦ê¶Œì†Œì†¡ê°œí˜ë²•(Private Securities Litigation Reform Act of 1995)ì˜ ì˜ë¯¸ ë‚´ì—ì„œ ë‹¤ìˆ˜ì˜ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ (forward-looking statements)ì„ í•˜ê²Œ ë  ê²ƒì„ì„ ìƒê¸°ì‹œì¼œ ë“œë¦½ë‹ˆë‹¤. ì‹¤ì œ ì¬ë¬´ ê²°ê³¼ë‚˜ ê¸°íƒ€ ì‚¬ê±´ë“¤ì´ ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì—ì„œ ëª…ì‹œëœ ê²ƒê³¼ ë‹¤ë¥¼ ìˆ˜ ìˆëŠ” ë§ì€ ìš”ì¸ë“¤ì´ ì¡´ì¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>I would refer you to the section of our earnings release titled Safe Harbor Statement, the safe harbor slide on the aforementioned PowerPoint presentation on our website, and our various filings with the SEC, including our annual reports on Form 10-K and our quarterly reports on Form 10-Q. We make no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today. We may refer to a number of non-GAAP financial measures, which are used in addition to, and in conjunction with, results presented in accordance with GAAP.</td><td>ë‹¹ì‚¬ì˜ ì‹¤ì  ë°œí‘œìë£Œ ì¤‘ ì•ˆì „í•­ ì¡°í•­(Safe Harbor Statement) ì„¹ì…˜, ì›¹ì‚¬ì´íŠ¸ì— ê²Œì‹œëœ íŒŒì›Œí¬ì¸íŠ¸ í”„ë ˆì  í…Œì´ì…˜ì˜ ì•ˆì „í•­ ìŠ¬ë¼ì´ë“œ, ê·¸ë¦¬ê³  ì—°ì°¨ë³´ê³ ì„œ(Form 10-K) ë° ë¶„ê¸°ë³´ê³ ì„œ(Form 10-Q)ë¥¼ í¬í•¨í•œ SEC ì œì¶œ ì„œë¥˜ë“¤ì„ ì°¸ì¡°í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. í–¥í›„ ì¬ë¬´ ë°ì´í„°ë‚˜ ì‚¬ê±´ì´ ì˜¤ëŠ˜ ì œì‹œëœ ì „ë§ ì§„ìˆ ê³¼ ë‹¤ë¥´ê²Œ ë°œìƒí•˜ë”ë¼ë„ ë‹¹ì‚¬ëŠ” ì´ëŸ¬í•œ ì§„ìˆ ì„ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ê°€ ì—†ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” GAAP ê¸°ì¤€ì— ë”°ë¼ ì œì‹œëœ ì‹¤ì ê³¼ í•¨ê»˜ ì¶”ê°€ì ìœ¼ë¡œ ì‚¬ìš©ë˜ëŠ” ì—¬ëŸ¬ ë¹„GAAP ì¬ë¬´ì§€í‘œë“¤ì„ ì–¸ê¸‰í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We believe the non-GAAP measures provide an additional way of viewing aspects of our operations and performance, but when considered with GAAP financial results and the reconciliation of the GAAP measures, they provide an even more complete understanding of the Azenta business. Non-GAAP measures should not be relied upon to the exclusion of the GAAP measures themselves. On the call with me today is our President and Chief Executive Officer, John Marotta, and our Executive Vice President and Chief Financial Officer, Lawrence Lin. We will open the call with remarks from John, then Lawrence will provide a detailed look into our financial results and our outlook for fiscal year 2026.</td><td>ì €í¬ëŠ” ë¹„-GAAP ì§€í‘œë“¤ì´ ë‹¹ì‚¬ì˜ ìš´ì˜ê³¼ ì„±ê³¼ë¥¼ ë°”ë¼ë³´ëŠ” ì¶”ê°€ì ì¸ ë°©ë²•ì„ ì œê³µí•œë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤ë§Œ, GAAP ì¬ë¬´ ê²°ê³¼ ë° GAAP ì§€í‘œì™€ì˜ ì¡°ì • ë‚´ì—­ê³¼ í•¨ê»˜ ê³ ë ¤í•  ë•Œ Azenta ì‚¬ì—…ì— ëŒ€í•œ ë”ìš± ì™„ì „í•œ ì´í•´ë¥¼ ì œê³µí•©ë‹ˆë‹¤. ë¹„-GAAP ì§€í‘œë“¤ì€ GAAP ì§€í‘œ ìì²´ë¥¼ ë°°ì œí•˜ê³  ì˜ì¡´í•´ì„œëŠ” ì•ˆ ë©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ëŠ” John Marotta ì‚¬ì¥ ê²¸ ìµœê³ ê²½ì˜ìì™€ Lawrence Lin ì „ë¬´ ê²¸ ìµœê³ ì¬ë¬´ì±…ì„ìê°€ í•¨ê»˜ í•˜ê³  ìˆìŠµë‹ˆë‹¤. Johnì˜ ë°œì–¸ìœ¼ë¡œ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ì‹œì‘í•˜ê² ìœ¼ë©°, ì´í›„ Lawrenceê°€ ë‹¹ì‚¬ì˜ ì¬ë¬´ ì‹¤ì ê³¼ 2026 íšŒê³„ì—°ë„ ì „ë§ì— ëŒ€í•´ ìƒì„¸íˆ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We will then take your questions at the end of their prepared remarks. With that, I would like to turn the call over to our CEO, John Marotta. John P. Marotta<br>President, CEO & Director<br><br>Thank you, Yvonne. Good morning, everyone, and thank you for joining us today. As we reflect on fiscal 2025, I want to begin by recognizing our Azenta employees around the world. Their dedication, resilience and unwavering focus on our customers and our purpose, enabling breakthroughs faster have been the driving force behind our successes to date.</td><td>ê°ì‚¬í•©ë‹ˆë‹¤, Yvonne. ì•ˆë…•í•˜ì„¸ìš”, ì—¬ëŸ¬ë¶„. ì˜¤ëŠ˜ ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. 2025 íšŒê³„ì—°ë„ë¥¼ ëŒì•„ë³´ë©´ì„œ, ë¨¼ì € ì „ ì„¸ê³„ Azenta ì„ì§ì›ë“¤ì—ê²Œ ê°ì‚¬ì˜ ë§ì”€ì„ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ê·¸ë“¤ì˜ í—Œì‹ , íšŒë³µë ¥, ê·¸ë¦¬ê³  ê³ ê°ê³¼ ìš°ë¦¬ì˜ ëª©í‘œì¸ 'í˜ì‹ ì„ ë” ë¹ ë¥´ê²Œ ì‹¤í˜„í•˜ëŠ” ê²ƒ(enabling breakthroughs faster)'ì— ëŒ€í•œ í”ë“¤ë¦¼ ì—†ëŠ” ì§‘ì¤‘ì´ ì§€ê¸ˆê¹Œì§€ ìš°ë¦¬ê°€ ì´ë£¬ ì„±ê³µì˜ ì›ë™ë ¥ì´ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>At the start of the year, we set out to refocus the organization, put the customer at the core of everything we do, to simplify how we operate, to improve execution, and to build a company positioned for durable, profitable growth and long-term value creation. We've made considerable progress, but we have also recognized we have more to do, which excites us about the road ahead. The opportunities in front of us are significant. We're energized by the potential to deepen our impact, sharpen our execution and continue delivering for our customers, our employees and our shareholders.</td><td>ì˜¬í•´ ì´ˆ, ìš°ë¦¬ëŠ” ì¡°ì§ì„ ì¬ì •ë¹„í•˜ê³  ê³ ê°ì„ ëª¨ë“  ì—…ë¬´ì˜ ì¤‘ì‹¬ì— ë‘ë©°, ìš´ì˜ ë°©ì‹ì„ ë‹¨ìˆœí™”í•˜ê³ , ì‹¤í–‰ë ¥ì„ ê°œì„ í•˜ë©°, ì§€ì† ê°€ëŠ¥í•œ ìˆ˜ìµì„± ì„±ì¥ê³¼ ì¥ê¸°ì  ê°€ì¹˜ ì°½ì¶œì„ ìœ„í•œ ê¸°ë°˜ì„ ê°–ì¶˜ íšŒì‚¬ë¥¼ êµ¬ì¶•í•˜ê³ ì í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìƒë‹¹í•œ ì§„ì „ì„ ì´ë£¨ì—ˆì§€ë§Œ, ë™ì‹œì— ë” í•´ì•¼ í•  ì¼ì´ ìˆë‹¤ëŠ” ê²ƒì„ ì¸ì‹í•˜ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ì•ìœ¼ë¡œì˜ ì—¬ì •ì— ëŒ€í•œ ê¸°ëŒ€ê°ì„ ë¶ˆëŸ¬ì¼ìœ¼í‚µë‹ˆë‹¤. ìš°ë¦¬ ì•ì— ë†“ì¸ ê¸°íšŒëŠ” ë§¤ìš° í½ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì˜í–¥ë ¥ì„ ì‹¬í™”í•˜ê³ , ì‹¤í–‰ë ¥ì„ ê°•í™”í•˜ë©°, ê³ ê°, ì„ì§ì›, ê·¸ë¦¬ê³  ì£¼ì£¼ ì—¬ëŸ¬ë¶„ì„ ìœ„í•´ ì§€ì†ì ìœ¼ë¡œ ì„±ê³¼ë¥¼ ì°½ì¶œí•  ìˆ˜ ìˆëŠ” ì ì¬ë ¥ì— í™œë ¥ì„ ì–»ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We've created a simpler, more accountable organization through the implementation of the Azenta Business System, ABS, which is the framework for how we operate. It brings together lean principles, daily management routines and structured problem solving. This year, we trained teams and conducted Kaizens in manufacturing, commercial and support functions, and delivered measurable improvements in quality, on-time delivery and overall productivity. These results are just the start. What's most meaningful is the cultural shift and momentum. Operational excellence is no longer just a goal. It's embedded in how our teams work every day.</td><td>ìš°ë¦¬ëŠ” Azenta Business System(ABS)ì˜ ë„ì…ì„ í†µí•´ ë”ìš± ë‹¨ìˆœí•˜ê³  ì±…ì„ê° ìˆëŠ” ì¡°ì§ì„ ë§Œë“¤ì–´ì™”ìŠµë‹ˆë‹¤. ABSëŠ” ìš°ë¦¬ì˜ ìš´ì˜ ë°©ì‹ì„ ìœ„í•œ í”„ë ˆì„ì›Œí¬ì…ë‹ˆë‹¤. ì´ëŠ” ë¦°(Lean) ì›ì¹™, ì¼ì¼ ê´€ë¦¬ ë£¨í‹´, ê·¸ë¦¬ê³  êµ¬ì¡°í™”ëœ ë¬¸ì œ í•´ê²° ë°©ì‹ì„ í†µí•©í•©ë‹ˆë‹¤. ì˜¬í•´ ìš°ë¦¬ëŠ” ì œì¡°, ì˜ì—… ë° ì§€ì› ë¶€ì„œì—ì„œ íŒ€ì„ êµìœ¡í•˜ê³  ì¹´ì´ì  (Kaizen)ì„ ì‹¤ì‹œí–ˆìœ¼ë©°, í’ˆì§ˆ, ì •ì‹œ ë‚©í’ˆë¥  ë° ì „ë°˜ì ì¸ ìƒì‚°ì„±ì—ì„œ ì¸¡ì • ê°€ëŠ¥í•œ ê°œì„ ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ê³¼ëŠ” ì‹œì‘ì— ë¶ˆê³¼í•©ë‹ˆë‹¤. ê°€ì¥ ì˜ë¯¸ ìˆëŠ” ê²ƒì€ ë¬¸í™”ì  ë³€í™”ì™€ ëª¨ë©˜í…€ì…ë‹ˆë‹¤. ìš´ì˜ ìš°ìˆ˜ì„±ì€ ë” ì´ìƒ ë‹¨ìˆœí•œ ëª©í‘œê°€ ì•„ë‹™ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ íŒ€ì´ ë§¤ì¼ ì¼í•˜ëŠ” ë°©ì‹ì— ë‚´ì¬ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Employees are identifying inefficiencies and driving change from the ground up. We have simplified our structure. We have moved from a complex centralized model to one that empowers our operating companies with clear accountability and a greater agility. Decision-making is now faster, closer to the customer and grounded in data and outcomes. We've reinvested savings in line with our growth priorities, innovation, sales, marketing and product management. These changes are making Azenta a more growth focused and efficient company.</td><td>ì§ì›ë“¤ì€ ë¹„íš¨ìœ¨ì„±ì„ íŒŒì•…í•˜ê³  í˜„ì¥ì—ì„œë¶€í„° ë³€í™”ë¥¼ ì£¼ë„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì¡°ì§ êµ¬ì¡°ë¥¼ ë‹¨ìˆœí™”í–ˆìŠµë‹ˆë‹¤. ë³µì¡í•œ ì¤‘ì•™ì§‘ì¤‘ì‹ ëª¨ë¸ì—ì„œ ëª…í™•í•œ ì±…ì„ì„±ê³¼ ë” í° ë¯¼ì²©ì„±ì„ ê°–ì¶˜ ìš´ì˜ íšŒì‚¬ë“¤ì— ê¶Œí•œì„ ë¶€ì—¬í•˜ëŠ” ëª¨ë¸ë¡œ ì „í™˜í–ˆìŠµë‹ˆë‹¤. ì˜ì‚¬ê²°ì •ì€ ì´ì œ ë” ë¹ ë¥´ê³ , ê³ ê°ì—ê²Œ ë” ê°€ê¹Œìš°ë©°, ë°ì´í„°ì™€ ì„±ê³¼ì— ê¸°ë°˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì ˆê°ëœ ë¹„ìš©ì„ ì„±ì¥ ìš°ì„ ìˆœìœ„ì¸ í˜ì‹ , ì˜ì—…, ë§ˆì¼€íŒ… ë° ì œí’ˆ ê´€ë¦¬ì— ì¬íˆ¬ìí–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë³€í™”ë“¤ì€ Azentaë¥¼ ë”ìš± ì„±ì¥ ì¤‘ì‹¬ì ì´ê³  íš¨ìœ¨ì ì¸ íšŒì‚¬ë¡œ ë§Œë“¤ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The strength of our balance sheet with over $0.5 billion in cash, cash equivalents and marketable securities gives us the financial flexibility to invest with discipline across 4 strategic levers driving productivity, accelerating organic growth, returning capital to shareholders through share repurchases, and pursuing targeted tuck-in M&A. We will have clear accountability for outcomes, reinforcing our commitment to value creation and operational excellence. We remain well positioned to invest for our future while delivering sustainable returns and creating long-term value. In fiscal 2025, we achieved 3% core growth and delivered meaningful margin expansion of 310 basis points.</td><td>5ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ í˜„ê¸ˆ, í˜„ê¸ˆì„±ìì‚° ë° ìœ ê°€ì¦ê¶Œì„ ë³´ìœ í•œ ê²¬ê³ í•œ ì¬ë¬´êµ¬ì¡°ëŠ” 4ê°€ì§€ ì „ëµì  ë ˆë²„ì— ê±¸ì³ ê·œìœ¨ ìˆëŠ” íˆ¬ìë¥¼ í•  ìˆ˜ ìˆëŠ” ì¬ë¬´ì  ìœ ì—°ì„±ì„ ì œê³µí•©ë‹ˆë‹¤. ì´ëŠ” ìƒì‚°ì„± í–¥ìƒ, ìœ ê¸°ì  ì„±ì¥ ê°€ì†í™”, ìì‚¬ì£¼ ë§¤ì…ì„ í†µí•œ ì£¼ì£¼ í™˜ì›, ê·¸ë¦¬ê³  ì„ ë³„ì ì¸ ì†Œê·œëª¨ ì¸ìˆ˜í•©ë³‘ ì¶”ì§„ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì„±ê³¼ì— ëŒ€í•œ ëª…í™•í•œ ì±…ì„ì„ ì§€ë©°, ê°€ì¹˜ ì°½ì¶œê³¼ ìš´ì˜ ìš°ìˆ˜ì„±ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì˜ì§€ë¥¼ ê°•í™”í•  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì§€ì† ê°€ëŠ¥í•œ ìˆ˜ìµì„ ì œê³µí•˜ê³  ì¥ê¸°ì  ê°€ì¹˜ë¥¼ ì°½ì¶œí•˜ë©´ì„œ ë¯¸ë˜ë¥¼ ìœ„í•œ íˆ¬ìë¥¼ í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. 2025 íšŒê³„ì—°ë„ì— ìš°ë¦¬ëŠ” 3%ì˜ í•µì‹¬ ì„±ì¥ì„ ë‹¬ì„±í–ˆìœ¼ë©° 310bpì˜ ì˜ë¯¸ ìˆëŠ” ë§ˆì§„ í™•ëŒ€ë¥¼ ì‹¤í˜„í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Beyond our financial results, we took decisive steps to reshape our commercial organization, with the right leadership in place and expanded field presence, and a sharpened go-to-market targeting. We're well positioned to serve our customers and accelerate our growth trajectory. It's important to recognize that all of this took place amid a volatile and uncertain macro backdrop, characterized by softer academic and NIH funding, shifting biopharma priorities and ongoing geopolitical uncertainty. Yet through these challenges, Azenta demonstrated its resilience.</td><td>ì¬ë¬´ ì‹¤ì  ì™¸ì—ë„, ìš°ë¦¬ëŠ” ì ì ˆí•œ ë¦¬ë”ì‹­ ë°°ì¹˜ì™€ í˜„ì¥ ì¸ë ¥ í™•ëŒ€, ê·¸ë¦¬ê³  ì‹œì¥ ì§„ì¶œ íƒ€ê²ŸíŒ… ê°•í™”ë¥¼ í†µí•´ ì˜ì—… ì¡°ì§ì„ ì¬í¸í•˜ëŠ” ë‹¨í˜¸í•œ ì¡°ì¹˜ë¥¼ ì·¨í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê³ ê°ì—ê²Œ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ê³  ì„±ì¥ ê¶¤ë„ë¥¼ ê°€ì†í™”í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒì´ í•™ê³„ ë° NIH ì—°êµ¬ë¹„ ê°ì†Œ, ë°”ì´ì˜¤ì œì•½ ìš°ì„ ìˆœìœ„ ë³€í™”, ì§€ì†ë˜ëŠ” ì§€ì •í•™ì  ë¶ˆí™•ì‹¤ì„±ìœ¼ë¡œ íŠ¹ì§•ì§€ì–´ì§€ëŠ” ë³€ë™ì„±ì´ í¬ê³  ë¶ˆí™•ì‹¤í•œ ê±°ì‹œê²½ì œ í™˜ê²½ ì†ì—ì„œ ì´ë£¨ì–´ì¡Œë‹¤ëŠ” ì ì„ ì¸ì‹í•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì´ëŸ¬í•œ ì–´ë ¤ì›€ ì†ì—ì„œë„ AzentaëŠ” íšŒë³µíƒ„ë ¥ì„±ì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our differentiated portfolio delivers critical solutions that uniquely support our customers, ranging from sample management of irreplaceable assets to automated product workflows, warehouse and inventory optimization, and comprehensive testing of samples and data that underpin life sciences research and production. We're confident not only in our ability to navigate volatility, but to capitalize on it. This environment has also created opportunities as customers look to do more with less, they are consolidating partners, outsourcing noncore operations, and investing in automation and digital workflows. All areas where Azenta is positioned to lead.</td><td>ì €í¬ì˜ ì°¨ë³„í™”ëœ í¬íŠ¸í´ë¦¬ì˜¤ëŠ” ê³ ê°ë“¤ì„ ë…ë³´ì ìœ¼ë¡œ ì§€ì›í•˜ëŠ” í•µì‹¬ ì†”ë£¨ì…˜ì„ ì œê³µí•©ë‹ˆë‹¤. ëŒ€ì²´ ë¶ˆê°€ëŠ¥í•œ ìì‚°ì˜ ìƒ˜í”Œ ê´€ë¦¬ë¶€í„° ìë™í™”ëœ ì œí’ˆ ì›Œí¬í”Œë¡œìš°, ì°½ê³  ë° ì¬ê³  ìµœì í™”, ê·¸ë¦¬ê³  ìƒëª…ê³¼í•™ ì—°êµ¬ ë° ìƒì‚°ì„ ë’·ë°›ì¹¨í•˜ëŠ” ìƒ˜í”Œê³¼ ë°ì´í„°ì˜ ì¢…í•©ì ì¸ í…ŒìŠ¤íŠ¸ì— ì´ë¥´ê¸°ê¹Œì§€ ë‹¤ì–‘í•œ ì˜ì—­ì„ ì•„ìš°ë¦…ë‹ˆë‹¤. ì €í¬ëŠ” ë³€ë™ì„±ì„ í—¤ì³ë‚˜ê°ˆ ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ë¿ë§Œ ì•„ë‹ˆë¼, ì´ë¥¼ ê¸°íšŒë¡œ í™œìš©í•  ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì—ë„ ìì‹ ê°ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ í™˜ê²½ì€ ê³ ê°ë“¤ì´ ë” ì ì€ ìì›ìœ¼ë¡œ ë” ë§ì€ ê²ƒì„ ë‹¬ì„±í•˜ê³ ì í•¨ì— ë”°ë¼ ê¸°íšŒë¥¼ ì°½ì¶œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê³ ê°ë“¤ì€ íŒŒíŠ¸ë„ˆë¥¼ í†µí•©í•˜ê³ , ë¹„í•µì‹¬ ìš´ì˜ì„ ì•„ì›ƒì†Œì‹±í•˜ë©°, ìë™í™” ë° ë””ì§€í„¸ ì›Œí¬í”Œë¡œìš°ì— íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ì˜ì—­ì´ ë°”ë¡œ Azentaê°€ ì„ ë„ì  ìœ„ì¹˜ë¥¼ ì í•˜ê³  ìˆëŠ” ë¶„ì•¼ì…ë‹ˆë‹¤.</td></tr>
<tr><td>We're seeing new partnership discussions emerge precisely because of our reputation for expertise, quality, reliability and execution. Our customers are looking for partners they can trust and Azenta is that partner. As we look ahead to fiscal 2026, we are entering the year from a position of strength. Although macroeconomic uncertainty continues to persist, we have reshaped the organization, instilled a culture of accountability, and continuous improvement, and set a strong operational foundation. Our priorities are clear.</td><td>ì „ë¬¸ì„±, í’ˆì§ˆ, ì‹ ë¢°ì„± ë° ì‹¤í–‰ë ¥ì— ëŒ€í•œ ë‹¹ì‚¬ì˜ ëª…ì„± ë•ë¶„ì— ìƒˆë¡œìš´ íŒŒíŠ¸ë„ˆì‹­ ë…¼ì˜ê°€ ì •í™•íˆ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ê³ ê°ë“¤ì€ ì‹ ë¢°í•  ìˆ˜ ìˆëŠ” íŒŒíŠ¸ë„ˆë¥¼ ì°¾ê³  ìˆìœ¼ë©°, Azentaê°€ ë°”ë¡œ ê·¸ íŒŒíŠ¸ë„ˆì…ë‹ˆë‹¤. 2026 íšŒê³„ì—°ë„ë¥¼ ì•ë‘ê³  ìˆëŠ” ì§€ê¸ˆ, ìš°ë¦¬ëŠ” ê°•ë ¥í•œ ì…ì§€ì—ì„œ í•œ í•´ë¥¼ ì‹œì‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê±°ì‹œê²½ì œì  ë¶ˆí™•ì‹¤ì„±ì´ ì§€ì†ë˜ê³  ìˆì§€ë§Œ, ìš°ë¦¬ëŠ” ì¡°ì§ì„ ì¬í¸í•˜ê³ , ì±…ì„ê°ê³¼ ì§€ì†ì  ê°œì„ ì˜ ë¬¸í™”ë¥¼ ì‹¬ì–´ì£¼ì—ˆìœ¼ë©°, ê²¬ê³ í•œ ìš´ì˜ ê¸°ë°˜ì„ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ìš°ì„ ìˆœìœ„ëŠ” ëª…í™•í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Continue to deliver core growth and margin expansion, embed the Azenta business system deeper across the organization to further improve our operational discipline and productivity, and to deploy capital optimally in a disciplined approach. We anticipate core revenue growth between 3% to 5%, and expected adjusted EBITDA margin expansion of 300 basis points, and higher free cash flow generation as we scale our operational improvements. With a leaner structure, growth initiatives, enhanced ABS discipline, and a strong balance sheet, we believe we're positioned to outperform the market.</td><td>í•µì‹¬ ì„±ì¥ê³¼ ë§ˆì§„ í™•ëŒ€ë¥¼ ì§€ì†ì ìœ¼ë¡œ ë‹¬ì„±í•˜ê³ , Azenta ë¹„ì¦ˆë‹ˆìŠ¤ ì‹œìŠ¤í…œì„ ì¡°ì§ ì „ë°˜ì— ë”ìš± ê¹Šì´ ë‚´ì¬í™”í•˜ì—¬ ìš´ì˜ ê·œìœ¨ê³¼ ìƒì‚°ì„±ì„ ë”ìš± ê°œì„ í•˜ë©°, ê·œìœ¨ ìˆëŠ” ì ‘ê·¼ ë°©ì‹ìœ¼ë¡œ ìë³¸ì„ ìµœì ìœ¼ë¡œ ë°°ì¹˜í•  ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 3%ì—ì„œ 5% ì‚¬ì´ì˜ í•µì‹¬ ë§¤ì¶œ ì„±ì¥ê³¼ 300bpì˜ ì¡°ì • EBITDA ë§ˆì§„ í™•ëŒ€, ê·¸ë¦¬ê³  ìš´ì˜ ê°œì„  í™•ëŒ€ì— ë”°ë¥¸ ë” ë†’ì€ ì‰ì—¬í˜„ê¸ˆíë¦„ ì°½ì¶œì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë³´ë‹¤ íš¨ìœ¨ì ì¸ êµ¬ì¡°, ì„±ì¥ ì´ë‹ˆì…”í‹°ë¸Œ, ê°•í™”ëœ ABS ê·œìœ¨, ê·¸ë¦¬ê³  íƒ„íƒ„í•œ ì¬ë¬´êµ¬ì¡°ë¥¼ ë°”íƒ•ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ì‹œì¥ì„ ìƒíšŒí•˜ëŠ” ì„±ê³¼ë¥¼ ë‚¼ ìˆ˜ ìˆëŠ” ìœ„ì¹˜ì— ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Next month, we will host our Investor Day where we will outline the next phase of the Azenta journey, including our multiyear growth strategy, long-term financial framework and capital deployment priorities. We look forward to sharing how our strategy positions us for profitable growth and value creation. We are a stronger company today operationally, culturally and strategically. And we are confident in the path ahead. With that, I'll turn the call over to Lawrence for a detailed review of our financial results. Lawrence Lin<br>Executive VP & CFO<br><br>Thank you, John, and good morning, everybody.</td><td>ë‹¤ìŒ ë‹¬ì—ëŠ” íˆ¬ììì˜ ë‚ (Investor Day)ì„ ê°œìµœí•˜ì—¬ ë‹¤ë…„ê°„ ì„±ì¥ ì „ëµ, ì¥ê¸° ì¬ë¬´ í”„ë ˆì„ì›Œí¬ ë° ìë³¸ ë°°ë¶„ ìš°ì„ ìˆœìœ„ë¥¼ í¬í•¨í•œ Azentaì˜ ë‹¤ìŒ ë‹¨ê³„ ì—¬ì •ì„ ì„¤ëª…í•  ì˜ˆì •ì…ë‹ˆë‹¤. ìš°ë¦¬ì˜ ì „ëµì´ ì–´ë–»ê²Œ ìˆ˜ìµì„± ìˆëŠ” ì„±ì¥ê³¼ ê°€ì¹˜ ì°½ì¶œì„ ìœ„í•œ ì…ì§€ë¥¼ ë§ˆë ¨í•˜ëŠ”ì§€ ê³µìœ í•  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì˜¤ëŠ˜ë‚  ìš´ì˜ì ìœ¼ë¡œ, ë¬¸í™”ì ìœ¼ë¡œ, ê·¸ë¦¬ê³  ì „ëµì ìœ¼ë¡œ ë”ìš± ê°•ë ¥í•œ íšŒì‚¬ê°€ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì•ìœ¼ë¡œì˜ ê¸¸ì— ëŒ€í•´ í™•ì‹ ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ì¬ë¬´ ì‹¤ì ì— ëŒ€í•œ ìƒì„¸í•œ ê²€í† ë¥¼ ìœ„í•´ Lawrenceì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Lawrence Lin<br>ìµœê³ ì¬ë¬´ì±…ì„ì(CFO) ê²¸ ì „ë¬´ì´ì‚¬<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, John. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤.</td></tr>
<tr><td>I'll start by sharing with you our fourth quarter and full year fiscal 2025 results, then discuss our segments, provide an update on our balance sheet, and then close with guidance for fiscal 2026. But first, I want to take a moment to echo John's comments. Fiscal 2025 was truly a pivotal year for Azenta. As we close the year, we're encouraged by the internal business momentum and excited to carry that progress forward into fiscal 2026. The results we are discussing today exclude B Medical Systems, which is reported in discontinued operations unless otherwise noted. In the fourth quarter, we recorded an additional noncash loss on assets held for sale of $4 million on B Medical.</td><td>ë¨¼ì € 2025 íšŒê³„ì—°ë„ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì ì„ ê³µìœ í•œ í›„, ì‚¬ì—…ë¶€ë¬¸ì— ëŒ€í•´ ë…¼ì˜í•˜ê³ , ì¬ë¬´ìƒíƒœí‘œ í˜„í™©ì„ ì—…ë°ì´íŠ¸í•œ ë‹¤ìŒ, 2026 íšŒê³„ì—°ë„ ê°€ì´ë˜ìŠ¤ë¡œ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ê·¸ ì „ì—, Johnì˜ ë§ì”€ì„ ë‹¤ì‹œ í•œë²ˆ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. 2025 íšŒê³„ì—°ë„ëŠ” Azentaì—ê²Œ ì§„ì •ìœ¼ë¡œ ì¤‘ìš”í•œ ì „í™˜ì ì´ ë˜ëŠ” í•´ì˜€ìŠµë‹ˆë‹¤. ì—°ë„ë¥¼ ë§ˆê°í•˜ë©´ì„œ, ìš°ë¦¬ëŠ” ë‚´ë¶€ ì‚¬ì—… ëª¨ë©˜í…€ì— ê³ ë¬´ë˜ì–´ ìˆìœ¼ë©°, ì´ëŸ¬í•œ ì§„ì „ì„ 2026 íšŒê³„ì—°ë„ë¡œ ì´ì–´ê°ˆ ìˆ˜ ìˆê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ì˜¤ëŠ˜ ë…¼ì˜í•˜ëŠ” ì‹¤ì ì€ ë³„ë„ë¡œ ì–¸ê¸‰í•˜ì§€ ì•ŠëŠ” í•œ ì¤‘ë‹¨ì‚¬ì—…ìœ¼ë¡œ ë³´ê³ ëœ B Medical Systemsë¥¼ ì œì™¸í•œ ê²ƒì…ë‹ˆë‹¤. 4ë¶„ê¸°ì— ìš°ë¦¬ëŠ” B Medicalì˜ ë§¤ê°ì˜ˆì •ìì‚°ì— ëŒ€í•´ 400ë§Œ ë‹¬ëŸ¬ì˜ ì¶”ê°€ ë¹„í˜„ê¸ˆ ì†ì‹¤ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We believe the transaction remains on track to be announced in calendar 2025. To supplement my remarks today, I will refer to the slide deck available on our website. We'll begin on Slide 4 with a few highlights. Fourth quarter revenue was $159 million, up 6% year-over-year on a reported basis, and up 4% organically with Multiomics delivering a record quarter. Fiscal year 2025 revenue was $594 million, which was up 4% on a reported basis, and up 3% organic, despite a macro environment that became more challenging as the year progresses.</td><td>ì €í¬ëŠ” ì´ë²ˆ ê±°ë˜ê°€ 2025ë…„ ì¤‘ ë°œí‘œë  ì˜ˆì •ëŒ€ë¡œ ì§„í–‰ë˜ê³  ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì œ ë°œì–¸ì„ ë³´ì™„í•˜ê¸° ìœ„í•´ ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ì—ì„œ ì œê³µë˜ëŠ” ìŠ¬ë¼ì´ë“œ ìë£Œë¥¼ ì°¸ê³ í•˜ê² ìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 4í˜ì´ì§€ì˜ ì£¼ìš” ë‚´ìš©ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. 4ë¶„ê¸° ë§¤ì¶œì€ 1ì–µ 5,900ë§Œ ë‹¬ëŸ¬ë¡œ ë³´ê³  ê¸°ì¤€ ì „ë…„ ëŒ€ë¹„ 6% ì¦ê°€í–ˆìœ¼ë©°, ìœ ê¸°ì  ì„±ì¥ë¥ ì€ 4%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë©€í‹°ì˜¤ë¯¹ìŠ¤(Multiomics) ë¶€ë¬¸ì€ ë¶„ê¸° ìµœê³  ì‹¤ì ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. 2025 íšŒê³„ì—°ë„ ë§¤ì¶œì€ 5ì–µ 9,400ë§Œ ë‹¬ëŸ¬ë¡œ ë³´ê³  ê¸°ì¤€ 4% ì¦ê°€í–ˆìœ¼ë©°, ìœ ê¸°ì  ì„±ì¥ë¥ ì€ 3%ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì—°ì¤‘ ê±°ì‹œê²½ì œ í™˜ê²½ì´ ì ì°¨ ì–´ë ¤ì›Œì¡ŒìŒì—ë„ ë¶ˆêµ¬í•˜ê³  ë‹¬ì„±í•œ ì„±ê³¼ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Strong performance in Next Generation Sequencing, Clinical Biostores, Sample Repository Solutions, and Consumables and Instruments contributed meaningfully to these results. Non-GAAP EPS for the fourth quarter was $0.21, and was $0.51 for the full year. I'm pleased to report an adjusted EBITDA margin of 13% in the fourth quarter, and 11.2% for the full year, representing expansion of approximately 230 basis points in Q4, and 310 basis points for the full year. These results reflect the continued benefits of our operational turnaround and disciplined cost execution, delivered in the face of a challenging macro environment.</td><td>ì°¨ì„¸ëŒ€ ì—¼ê¸°ì„œì—´ ë¶„ì„(NGS), ì„ìƒ ë°”ì´ì˜¤ìŠ¤í† ì–´, ìƒ˜í”Œ ë³´ê´€ ì†”ë£¨ì…˜, ê·¸ë¦¬ê³  ì†Œëª¨í’ˆ ë° ê¸°ê¸° ë¶€ë¬¸ì˜ ê²¬ì¡°í•œ ì‹¤ì ì´ ì´ëŸ¬í•œ ì„±ê³¼ì— ì˜ë¯¸ ìˆê²Œ ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° Non-GAAP EPSëŠ” 0.21ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ì—°ê°„ìœ¼ë¡œëŠ” 0.51ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ì¡°ì • EBITDA ë§ˆì§„ì€ 13%, ì—°ê°„ìœ¼ë¡œëŠ” 11.2%ë¥¼ ë‹¬ì„±í–ˆë‹¤ëŠ” ì ì„ ê¸°ì˜ê²Œ ë³´ê³ ë“œë¦½ë‹ˆë‹¤. ì´ëŠ” 4ë¶„ê¸°ì— ì•½ 230bp(ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸), ì—°ê°„ìœ¼ë¡œëŠ” 310bpì˜ ë§ˆì§„ í™•ëŒ€ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹¤ì ì€ ì–´ë ¤ìš´ ê±°ì‹œê²½ì œ í™˜ê²½ ì†ì—ì„œë„ ìš°ë¦¬ì˜ ìš´ì˜ ê°œì„ ê³¼ ì—„ê²©í•œ ë¹„ìš© ê´€ë¦¬ê°€ ì§€ì†ì ìœ¼ë¡œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŒì„ ë³´ì—¬ì¤ë‹ˆë‹¤.</td></tr>
<tr><td>We believe we have meaningfully more margin expansion potential and are confident we can achieve it while also accelerating our top line growth. Free cash flow, including B Medical, was a usage of $6 million for the quarter, driven by the timing of revenue and project-related milestone billing. For the full year, free cash flow was $38 million, a notable improvement of $26 million year-over-year, driven by improvements in working capital. Excluding B Medical, we ended the year in a strong financial position with $546 million in cash, cash equivalents and marketable securities, providing us with the flexibility to invest in growth initiatives and return value to shareholders over time.</td><td>ì €í¬ëŠ” ì˜ë¯¸ ìˆëŠ” ìˆ˜ì¤€ì˜ ë§ˆì§„ í™•ëŒ€ ì ì¬ë ¥ì„ ë³´ìœ í•˜ê³  ìˆë‹¤ê³  ë¯¿ìœ¼ë©°, ë§¤ì¶œ ì„±ì¥ì„ ê°€ì†í™”í•˜ë©´ì„œë„ ì´ë¥¼ ë‹¬ì„±í•  ìˆ˜ ìˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤. B Medicalì„ í¬í•¨í•œ ì‰ì—¬í˜„ê¸ˆíë¦„ì€ ë§¤ì¶œ ì¸ì‹ ì‹œê¸°ì™€ í”„ë¡œì íŠ¸ ê´€ë ¨ ë§ˆì¼ìŠ¤í†¤ ì²­êµ¬ ì‹œì ì˜ ì˜í–¥ìœ¼ë¡œ ë‹¹ ë¶„ê¸° 600ë§Œ ë‹¬ëŸ¬ì˜ ìœ ì¶œì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œëŠ” ì‰ì—¬í˜„ê¸ˆíë¦„ì´ 3,800ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ì—¬ ìš´ì „ìë³¸ ê°œì„ ì— í˜ì…ì–´ ì „ë…„ ëŒ€ë¹„ 2,600ë§Œ ë‹¬ëŸ¬ì˜ ì˜ë¯¸ ìˆëŠ” ê°œì„ ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. B Medicalì„ ì œì™¸í•˜ê³  ì—°ë§ ê¸°ì¤€ í˜„ê¸ˆ, í˜„ê¸ˆì„±ìì‚° ë° ìœ ê°€ì¦ê¶Œì€ 5ì–µ 4,600ë§Œ ë‹¬ëŸ¬ë¡œ ê°•ë ¥í•œ ì¬ë¬´ ìƒíƒœë¥¼ ìœ ì§€í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì„±ì¥ ì´ë‹ˆì…”í‹°ë¸Œì— íˆ¬ìí•˜ê³  ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ì£¼ì£¼ë“¤ì—ê²Œ ê°€ì¹˜ë¥¼ í™˜ì›í•  ìˆ˜ ìˆëŠ” ìœ ì—°ì„±ì„ ì œê³µí•©ë‹ˆë‹¤.</td></tr>
<tr><td>We closed fiscal 2025 with a healthier, more efficient business, sustained operational momentum and the financial strength to invest in our growth priorities. Now let's turn to Slide 5 to take a deeper look at our results in the quarter. Total revenue of $159 million represented a 6% growth on a reported basis, and 4% on an organic basis. As I already mentioned, Multiomics delivered a record quarter. Solid contributions from Next Generation Sequencing, Automated Stores and Sample Storage were the primary driver of growth that helped offset softness in other areas of the portfolio. In the fourth quarter, non-GAAP gross margin was 46.7%, down 20 basis points year-over-year.</td><td>2025 íšŒê³„ì—°ë„ë¥¼ ë§ˆë¬´ë¦¬í•˜ë©´ì„œ ìš°ë¦¬ëŠ” ë”ìš± ê±´ê°•í•˜ê³  íš¨ìœ¨ì ì¸ ì‚¬ì—…, ì§€ì†ì ì¸ ìš´ì˜ ëª¨ë©˜í…€, ê·¸ë¦¬ê³  ì„±ì¥ ìš°ì„ ìˆœìœ„ì— íˆ¬ìí•  ìˆ˜ ìˆëŠ” ì¬ë¬´ì  ê±´ì „ì„±ì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 5ë¡œ ë„˜ì–´ê°€ì„œ ì´ë²ˆ ë¶„ê¸° ì‹¤ì ì„ ì¢€ ë” ìì„¸íˆ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ì´ ë§¤ì¶œì€ 1ì–µ 5,900ë§Œ ë‹¬ëŸ¬ë¡œ ë³´ê³  ê¸°ì¤€ 6% ì„±ì¥, ìœ ê¸°ì  ê¸°ì¤€ìœ¼ë¡œëŠ” 4% ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ë©€í‹°ì˜¤ë¯¹ìŠ¤(Multiomics) ë¶€ë¬¸ì´ ë¶„ê¸° ìµœê³  ì‹¤ì ì„ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. ì°¨ì„¸ëŒ€ ì—¼ê¸°ì„œì—´ë¶„ì„(Next Generation Sequencing), ìë™í™” ë³´ê´€ì‹œìŠ¤í…œ(Automated Stores), ìƒ˜í”Œ ë³´ê´€(Sample Storage) ë¶€ë¬¸ì˜ ê²¬ì¡°í•œ ê¸°ì—¬ê°€ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´ ë‹¤ë¥¸ ì˜ì—­ì˜ ë¶€ì§„ì„ ìƒì‡„í•˜ë©° ì„±ì¥ì„ ê²¬ì¸í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ë¹„-GAAP ë§¤ì¶œì´ì´ìµë¥ ì€ 46.7%ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 20bp(ë² ì´ì‹œìŠ¤í¬ì¸íŠ¸) ê°ì†Œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The modest decline was driven by performance in Multiomics, partially offset by favorable product mix, gains from operational efficiencies and improved cost execution, mainly in Sample Management Solutions. Overall, the net impact was limited, demonstrating the resilience of our business amid a challenging macro environment. Adjusted EBITDA was $21 million, representing 13% margin, expanding both year-over-year and sequentially. This improvement reflects the leverage from our cost actions and our disciplined focus on operational performance. Again, non-GAAP EPS was $0.21 per share.</td><td>ì´ëŸ¬í•œ ì†Œí­ í•˜ë½ì€ Multiomics ë¶€ë¬¸ì˜ ì‹¤ì ì— ê¸°ì¸í–ˆìœ¼ë©°, ìœ ë¦¬í•œ ì œí’ˆ ë¯¹ìŠ¤, ìš´ì˜ íš¨ìœ¨ì„± ê°œì„  ë° ë¹„ìš© ì§‘í–‰ ê°œì„ (ì£¼ë¡œ Sample Management Solutions ë¶€ë¬¸)ìœ¼ë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ìˆœì˜í–¥ì€ ì œí•œì ì´ì—ˆìœ¼ë©°, ì´ëŠ” ì–´ë ¤ìš´ ê±°ì‹œê²½ì œ í™˜ê²½ ì†ì—ì„œë„ ìš°ë¦¬ ì‚¬ì—…ì˜ íšŒë³µë ¥ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ì¡°ì • EBITDAëŠ” 2,100ë§Œ ë‹¬ëŸ¬ë¡œ 13%ì˜ ë§ˆì§„ì„ ê¸°ë¡í–ˆìœ¼ë©°, ì „ë…„ ë™ê¸° ëŒ€ë¹„ ë° ì „ë¶„ê¸° ëŒ€ë¹„ ëª¨ë‘ í™•ëŒ€ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê°œì„ ì€ ë¹„ìš© ì ˆê° ì¡°ì¹˜ë¡œ ì¸í•œ ë ˆë²„ë¦¬ì§€ íš¨ê³¼ì™€ ìš´ì˜ ì„±ê³¼ì— ëŒ€í•œ ê·œìœ¨ ìˆëŠ” ì§‘ì¤‘ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ë©´, Non-GAAP EPSëŠ” ì£¼ë‹¹ 0.21ë‹¬ëŸ¬ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Overall, these results underscore consistent progress towards our profitability objectives, driven by improved efficiency, disciplined cost management and stronger execution. With that, let's turn to Slide 6 for a review of our segment quarterly results, starting with Sample Management Solutions, or SMS. SMS revenue was $86 million for the quarter, up 2% reported and flat organically. The performance reflects softness in Cryogenic Stores, driven by slower bookings due to ongoing customer budget constraints and a tough compare to last year's record quarter. Consumables and Instruments performed well both year-over-year and quarter-to-quarter.</td><td>ì „ë°˜ì ìœ¼ë¡œ ì´ëŸ¬í•œ ì‹¤ì ì€ ê°œì„ ëœ íš¨ìœ¨ì„±, ê·œìœ¨ ìˆëŠ” ë¹„ìš© ê´€ë¦¬, ê·¸ë¦¬ê³  ê°•ë ¥í•œ ì‹¤í–‰ë ¥ì— í˜ì…ì–´ ìˆ˜ìµì„± ëª©í‘œë¥¼ í–¥í•œ ì§€ì†ì ì¸ ì§„ì „ì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ìŠ¬ë¼ì´ë“œ 6ìœ¼ë¡œ ë„˜ì–´ê°€ì„œ ë¶„ê¸°ë³„ ì‚¬ì—…ë¶€ë¬¸ ì‹¤ì ì„ ê²€í† í•˜ê² ìŠµë‹ˆë‹¤. ë¨¼ì € Sample Management Solutions, ì¦‰ SMSë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. SMS ë§¤ì¶œì€ ë¶„ê¸° ê¸°ì¤€ 8,600ë§Œ ë‹¬ëŸ¬ë¡œ ë³´ê³  ê¸°ì¤€ 2% ì¦ê°€í–ˆìœ¼ë©°, ìœ ê¸°ì ìœ¼ë¡œëŠ” ë³´í•©ì„¸ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì‹¤ì ì€ ì§€ì†ë˜ëŠ” ê³ ê°ì‚¬ì˜ ì˜ˆì‚° ì œì•½ìœ¼ë¡œ ì¸í•œ ì£¼ë¬¸ ê°ì†Œì™€ ì‘ë…„ ê¸°ë¡ì ì¸ ë¶„ê¸°ì™€ì˜ ì–´ë ¤ìš´ ë¹„êµ ê¸°ì €ë¡œ ì¸í•´ Cryogenic Stores ë¶€ë¬¸ì˜ ë¶€ì§„ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. Consumablesì™€ InstrumentsëŠ” ì „ë…„ ë™ê¸° ëŒ€ë¹„ ë° ì „ë¶„ê¸° ëŒ€ë¹„ ëª¨ë‘ ì–‘í˜¸í•œ ì„±ê³¼ë¥¼ ë³´ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>While both Automated Stores and Sample Storage grew, customers continue to delay CapEx decisions due to macroeconomic uncertainty. SMS fourth quarter non-GAAP gross margin was 49.3%, up 180 basis points year-over-year, as a result of a favorable shift in product mix and improved operational execution and cost management. Turning next to the Multiomics segment. Multiomics delivered record revenue of $73 million in the quarter, the highest ever for the segment, representing 11% growth on a reported basis and 10% organic growth. Continued strength in Next Generation Sequencing was the primary driver with sequencing volume rising 50% year-over-year.</td><td>ìë™í™” ìŠ¤í† ì–´ì™€ ìƒ˜í”Œ ìŠ¤í† ë¦¬ì§€ ëª¨ë‘ ì„±ì¥í–ˆì§€ë§Œ, ê³ ê°ë“¤ì€ ê±°ì‹œê²½ì œì  ë¶ˆí™•ì‹¤ì„±ìœ¼ë¡œ ì¸í•´ ìë³¸ì  ì§€ì¶œ(CapEx) ê²°ì •ì„ ê³„ì† ì§€ì—°í•˜ê³  ìˆìŠµë‹ˆë‹¤. SMSì˜ 4ë¶„ê¸° ë¹„-GAAP ë§¤ì¶œì´ì´ìµë¥ ì€ 49.3%ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 180bp(ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸) ìƒìŠ¹í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì œí’ˆ ë¯¹ìŠ¤ì˜ ìœ ë¦¬í•œ ë³€í™”ì™€ ê°œì„ ëœ ìš´ì˜ ì‹¤í–‰ ë° ë¹„ìš© ê´€ë¦¬ì˜ ê²°ê³¼ì…ë‹ˆë‹¤. ë‹¤ìŒìœ¼ë¡œ ë©€í‹°ì˜¤ë¯¹ìŠ¤ ë¶€ë¬¸ì„ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ë©€í‹°ì˜¤ë¯¹ìŠ¤ëŠ” 4ë¶„ê¸°ì— 7,300ë§Œ ë‹¬ëŸ¬ì˜ ê¸°ë¡ì ì¸ ë§¤ì¶œì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” í•´ë‹¹ ë¶€ë¬¸ ì—­ëŒ€ ìµœê³ ì¹˜ë¡œ ë³´ê³  ê¸°ì¤€ 11% ì„±ì¥, ìœ ê¸°ì  ì„±ì¥ 10%ë¥¼ ë‚˜íƒ€ëƒ…ë‹ˆë‹¤. ì°¨ì„¸ëŒ€ ì—¼ê¸°ì„œì—´ë¶„ì„(NGS)ì˜ ì§€ì†ì ì¸ ê°•ì„¸ê°€ ì£¼ìš” ë™ë ¥ì´ì—ˆìœ¼ë©°, ì—¼ê¸°ì„œì—´ë¶„ì„ ë³¼ë¥¨ì´ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 50% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We saw a strong performance across all geographies, aided by large deals in Europe that contributed to the record quarterly revenue. Despite macro and geopolitical headwinds, our team continues to outperform in China, posting 17% organic growth for the quarter. Encouragingly, Gene Synthesis revenue grew low single digits year-over-year, achieving the highest quarterly revenue in 2025, driven by strong demand in China and continued wins in oligo production. We continue to actively monitor the macro environment where customers are reprioritizing projects and remapping pipelines.</td><td>ëª¨ë“  ì§€ì—­ì—ì„œ ê°•ë ¥í•œ ì‹¤ì ì„ ê¸°ë¡í–ˆìœ¼ë©°, ìœ ëŸ½ì˜ ëŒ€í˜• ê³„ì•½ë“¤ì´ ë¶„ê¸° ìµœê³  ë§¤ì¶œ ë‹¬ì„±ì— ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. ê±°ì‹œê²½ì œ ë° ì§€ì •í•™ì  ì—­í’ì—ë„ ë¶ˆêµ¬í•˜ê³ , ì¤‘êµ­ íŒ€ì€ ë¶„ê¸° 17%ì˜ ìœ ê¸°ì  ì„±ì¥ì„ ê¸°ë¡í•˜ë©° ì§€ì†ì ìœ¼ë¡œ ìš°ìˆ˜í•œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ê³ ë¬´ì ì¸ ì ì€ Gene Synthesis ë§¤ì¶œì´ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í•˜ì—¬ 2025ë…„ ë¶„ê¸° ìµœê³  ë§¤ì¶œì„ ê¸°ë¡í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” ì¤‘êµ­ì˜ ê°•ë ¥í•œ ìˆ˜ìš”ì™€ ì˜¬ë¦¬ê³  ìƒì‚° ë¶€ë¬¸ì˜ ì§€ì†ì ì¸ ìˆ˜ì£¼ ì¦ê°€ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê³ ê°ë“¤ì´ í”„ë¡œì íŠ¸ ìš°ì„ ìˆœìœ„ë¥¼ ì¬ì¡°ì •í•˜ê³  íŒŒì´í”„ë¼ì¸ì„ ì¬í¸ì„±í•˜ê³  ìˆëŠ” ê±°ì‹œê²½ì œ í™˜ê²½ì„ ì§€ì†ì ìœ¼ë¡œ ë©´ë°€íˆ ëª¨ë‹ˆí„°ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Sanger Sequencing revenue declined low double digit year-over-year, consistent with trends we've discussed in prior quarters, though the pace of decline moderated in the quarter. Revenue growth in Plasmid-EZ, our Oxford Nanopore-based solution, remains strong and continues to largely offset the decline in traditional Sanger revenue. Multiomics non-GAAP gross margin for the fourth quarter was 43.7%, down 260 basis points year-over-year. The decline was primarily driven by product mix and lower volume in Sanger Sequencing and Gene Synthesis. Now let's turn to Slide 7 for a review of the balance sheet.</td><td>ìƒì–´ ì‹œí€€ì‹±(Sanger Sequencing) ë§¤ì¶œì€ ì „ë…„ ëŒ€ë¹„ ë‚®ì€ ë‘ ìë¦¿ìˆ˜ ê°ì†Œë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ì´ì „ ë¶„ê¸°ë“¤ì—ì„œ ë…¼ì˜í–ˆë˜ ì¶”ì„¸ì™€ ì¼ì¹˜í•©ë‹ˆë‹¤. ë‹¤ë§Œ ê°ì†Œ ì†ë„ëŠ” ì´ë²ˆ ë¶„ê¸°ì— ë‹¤ì†Œ ì™„í™”ë˜ì—ˆìŠµë‹ˆë‹¤. ì˜¥ìŠ¤í¬ë“œ ë‚˜ë…¸í¬ì–´(Oxford Nanopore) ê¸°ë°˜ ì†”ë£¨ì…˜ì¸ Plasmid-EZì˜ ë§¤ì¶œ ì„±ì¥ì€ ì—¬ì „íˆ ê²¬ì¡°í•˜ë©°, ê¸°ì¡´ ìƒì–´ ì‹œí€€ì‹± ë§¤ì¶œ ê°ì†Œë¶„ì„ ìƒë‹¹ ë¶€ë¶„ ìƒì‡„í•˜ê³  ìˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ë©€í‹°ì˜¤ë¯¹ìŠ¤(Multiomics) ë¶€ë¬¸ì˜ ë¹„-GAAP ë§¤ì¶œì´ì´ìµë¥ ì€ 43.7%ë¡œ ì „ë…„ ëŒ€ë¹„ 260bp(ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸) ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê°ì†ŒëŠ” ì£¼ë¡œ ì œí’ˆ ë¯¹ìŠ¤ ë³€í™”ì™€ ìƒì–´ ì‹œí€€ì‹± ë° ìœ ì „ì í•©ì„±(Gene Synthesis) ë¶€ë¬¸ì˜ ë¬¼ëŸ‰ ê°ì†Œì— ê¸°ì¸í•©ë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 7ë¡œ ë„˜ì–´ê°€ì„œ ëŒ€ì°¨ëŒ€ì¡°í‘œë¥¼ ê²€í† í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We ended the year with $546 million in cash, cash equivalents and marketable securities, excluding B Medical. We had no debt outstanding. This strong liquidity position provides us with the strategic flexibility to invest in growth initiatives, support operational needs, and maintain a disciplined capital allocation framework. Capital expenditures for the quarter were approximately $8 million, reflecting continued investment in automation, capacity expansion and technology to support scalable growth. Turning to guidance on Slide 9. For fiscal 2026, we anticipate organic revenue growth in the range of 3% to 5%.</td><td>ì €í¬ëŠ” B Medicalì„ ì œì™¸í•˜ê³  í˜„ê¸ˆ, í˜„ê¸ˆì„±ìì‚° ë° ìœ ê°€ì¦ê¶Œ 5ì–µ 4,600ë§Œ ë‹¬ëŸ¬ë¥¼ ë³´ìœ í•œ ì±„ë¡œ ì—°ë„ë¥¼ ë§ˆê°í–ˆìŠµë‹ˆë‹¤. ë¯¸ìƒí™˜ ë¶€ì±„ëŠ” ì—†ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê°•ë ¥í•œ ìœ ë™ì„± í¬ì§€ì…˜ì€ ì„±ì¥ ì´ë‹ˆì…”í‹°ë¸Œì— íˆ¬ìí•˜ê³ , ìš´ì˜ ìˆ˜ìš”ë¥¼ ì§€ì›í•˜ë©°, ê·œìœ¨ ìˆëŠ” ìë³¸ ë°°ë¶„ í”„ë ˆì„ì›Œí¬ë¥¼ ìœ ì§€í•  ìˆ˜ ìˆëŠ” ì „ëµì  ìœ ì—°ì„±ì„ ì œê³µí•©ë‹ˆë‹¤. ë¶„ê¸° ìë³¸ì  ì§€ì¶œì€ ì•½ 800ë§Œ ë‹¬ëŸ¬ë¡œ, í™•ì¥ ê°€ëŠ¥í•œ ì„±ì¥ì„ ì§€ì›í•˜ê¸° ìœ„í•œ ìë™í™”, ìƒì‚°ëŠ¥ë ¥ í™•ëŒ€ ë° ê¸°ìˆ ì— ëŒ€í•œ ì§€ì†ì ì¸ íˆ¬ìë¥¼ ë°˜ì˜í•©ë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 9ì˜ ê°€ì´ë˜ìŠ¤ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 2026 íšŒê³„ì—°ë„ì˜ ê²½ìš°, ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥ ì„ 3%ì—ì„œ 5% ë²”ìœ„ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Multiomics is expected to deliver low single-digit growth, while Sample Management Solutions is expected to contribute mid-single-digit growth. Our guidance reflects continued uncertainty in the macro environment, particularly around capital spending, as well as moderated growth in Next Generation Sequencing as volumes normalize. Based on these factors, we expect a slower start in the first half of the year and anticipate first quarter revenue to decline approximately 1% to 2% year-over-year. We expect the second half of the year to accelerate as our commercial investments and growth initiatives game traction giving us confidence in our full year guide.</td><td>ë©€í‹°ì˜¤ë¯¹ìŠ¤ëŠ” ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ìƒ˜í”Œ ê´€ë¦¬ ì†”ë£¨ì…˜ì€ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì— ê¸°ì—¬í•  ê²ƒìœ¼ë¡œ ì „ë§ë©ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ê°€ì´ë˜ìŠ¤ëŠ” ê±°ì‹œê²½ì œ í™˜ê²½, íŠ¹íˆ ìë³¸ ì§€ì¶œê³¼ ê´€ë ¨ëœ ì§€ì†ì ì¸ ë¶ˆí™•ì‹¤ì„±ê³¼ í•¨ê»˜ ë¬¼ëŸ‰ì´ ì •ìƒí™”ë¨ì— ë”°ë¥¸ ì°¨ì„¸ëŒ€ ì‹œí€€ì‹±ì˜ ì™„ë§Œí•œ ì„±ì¥ì„ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìš”ì¸ë“¤ì„ ê³ ë ¤í•  ë•Œ, ìƒë°˜ê¸°ì—ëŠ” ë‹¤ì†Œ ëŠë¦° ì¶œë°œì´ ì˜ˆìƒë˜ë©° 1ë¶„ê¸° ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ì•½ 1%~2% ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. í•˜ë°˜ê¸°ì—ëŠ” ë‹¹ì‚¬ì˜ ì˜ì—… íˆ¬ìì™€ ì„±ì¥ ì´ë‹ˆì…”í‹°ë¸Œê°€ íƒ„ë ¥ì„ ë°›ìœ¼ë©´ì„œ ê°€ì†í™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” ì—°ê°„ ê°€ì´ë˜ìŠ¤ì— ëŒ€í•œ í™•ì‹ ì„ ê°–ê²Œ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>On the profitability front, we are targeting approximately 300 basis points of year-over-year adjusted EBITDA margin expansion, driven by continued operational efficiencies, disciplined cost management and scalable operating leverage. We expect to improve free cash flow generation by over 30% year-over-year. We look forward to sharing more information about our growth priorities and longer-term financial and capital allocation framework at our Investor Day in December. We will outline how these strategic initiatives position Azenta for sustainable, profitable growth and most importantly, value creation. In closing, we are pleased with our performance in fiscal 2025.</td><td>ìˆ˜ìµì„± ì¸¡ë©´ì—ì„œëŠ” ì§€ì†ì ì¸ ìš´ì˜ íš¨ìœ¨ì„± ê°œì„ , ì—„ê²©í•œ ë¹„ìš© ê´€ë¦¬, ê·¸ë¦¬ê³  í™•ì¥ ê°€ëŠ¥í•œ ìš´ì˜ ë ˆë²„ë¦¬ì§€ë¥¼ í†µí•´ ì¡°ì • EBITDA ë§ˆì§„ì´ ì „ë…„ ëŒ€ë¹„ ì•½ 300bp(ë² ì´ì‹œìŠ¤ í¬ì¸íŠ¸) í™•ëŒ€ë  ê²ƒìœ¼ë¡œ ëª©í‘œí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì‰ì—¬í˜„ê¸ˆíë¦„ ì°½ì¶œì€ ì „ë…„ ëŒ€ë¹„ 30% ì´ìƒ ê°œì„ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. 12ì›” íˆ¬ììì˜ ë‚ (Investor Day)ì—ì„œ ë‹¹ì‚¬ì˜ ì„±ì¥ ìš°ì„ ìˆœìœ„ì™€ ì¤‘ì¥ê¸° ì¬ë¬´ ë° ìë³¸ë°°ë¶„ í”„ë ˆì„ì›Œí¬ì— ëŒ€í•œ ë” ìì„¸í•œ ì •ë³´ë¥¼ ê³µìœ í•  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì „ëµì  ì´ë‹ˆì…”í‹°ë¸Œë“¤ì´ ì–´ë–»ê²Œ Azentaë¥¼ ì§€ì† ê°€ëŠ¥í•˜ê³  ìˆ˜ìµì„± ìˆëŠ” ì„±ì¥, ê·¸ë¦¬ê³  ë¬´ì—‡ë³´ë‹¤ ì¤‘ìš”í•œ ê°€ì¹˜ ì°½ì¶œì„ ìœ„í•œ ìœ„ì¹˜ì— ì˜¬ë ¤ë†“ëŠ”ì§€ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, 2025 íšŒê³„ì—°ë„ ì‹¤ì ì— ëŒ€í•´ ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>we reshaped the company structure, strengthened our operational foundation and generated strong financial results, despite a challenging macro environment. The progress we've made positions us well for fiscal 2026. This concludes our prepared remarks, and I will now turn the call over to the operator for questions.</td><td>ì–´ë ¤ìš´ ê±°ì‹œê²½ì œ í™˜ê²½ì—ë„ ë¶ˆêµ¬í•˜ê³  íšŒì‚¬ êµ¬ì¡°ë¥¼ ì¬í¸í•˜ê³ , ìš´ì˜ ê¸°ë°˜ì„ ê°•í™”í–ˆìœ¼ë©°, ê²¬ê³ í•œ ì¬ë¬´ ì„±ê³¼ë¥¼ ì°½ì¶œí–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ê°€ ì´ë£¬ ì´ëŸ¬í•œ ì§„ì „ì€ 2026 íšŒê³„ì—°ë„ë¥¼ ìœ„í•œ ì¢‹ì€ ìœ„ì¹˜ë¥¼ í™•ë³´í•˜ê²Œ í•´ì¤ë‹ˆë‹¤. ì´ê²ƒìœ¼ë¡œ ì¤€ë¹„ëœ ë°œì–¸ì„ ë§ˆì¹˜ê² ìœ¼ë©°, ì´ì œ ì§ˆì˜ì‘ë‹µì„ ìœ„í•´ êµí™˜ì›ì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Azenta (AZTA) 2025 íšŒê³„ì—°ë„ 4ë¶„ê¸° ì‹¤ì  ìš”ì•½<br><br>## í•µì‹¬ ë‚´ìš©<br><br>â€¢ **ì‹¤ì  ë° ì„±ì¥**: 4ë¶„ê¸° ë§¤ì¶œ $159M(ì „ë…„ ëŒ€ë¹„ ë³´ê³  ê¸°ì¤€ +6%, ìœ ê¸°ì  +4%), ì—°ê°„ ë§¤ì¶œ $594M(ë³´ê³  ê¸°ì¤€ +4%, ìœ ê¸°ì  +3%). Multiomics ë¶€ë¬¸ì´ ì‚¬ìƒ ìµœê³  ë¶„ê¸° ì‹¤ì ($73M, +11%)ì„ ê¸°ë¡í–ˆìœ¼ë©°, NGS ì‹œí€€ì‹± ë³¼ë¥¨ì´ ì „ë…„ ëŒ€ë¹„ 50% ì¦ê°€. ë¹„GAAP EPSëŠ” 4ë¶„ê¸° $0.21, ì—°ê°„ $0.51.<br><br>â€¢ **ìˆ˜ìµì„± ê°œì„ **: ì¡°ì • EBITDA ë§ˆì§„ì´ 4ë¶„ê¸° 13%(ì „ë…„ ëŒ€ë¹„ +230bp), ì—°ê°„ 11.2%(+310bp)ë¡œ í¬ê²Œ í™•ëŒ€. ìš´ì˜ íš¨ìœ¨ì„± ê°œì„ ê³¼ ë¹„ìš© ê´€ë¦¬ ê°•í™”ê°€ ì£¼ìš” ë™ì¸. ì‰ì—¬í˜„ê¸ˆíë¦„ì€ ì—°ê°„ $38Më¡œ ì „ë…„ ëŒ€ë¹„ $26M ê°œì„ . í˜„ê¸ˆ ë° ìœ ê°€ì¦ê¶Œ $546M ë³´ìœ ë¡œ ê°•ë ¥í•œ ì¬ë¬´ ìœ ì—°ì„± í™•ë³´.<br><br>â€¢ **2026 íšŒê³„ì—°ë„ ê°€ì´ë˜ìŠ¤**: ìœ ê¸°ì  ë§¤ì¶œ ì„±ì¥ë¥  3~5% ì „ë§(Multiomics ì €ë‹¨ì¼ìë¦¿ìˆ˜, SMS ì¤‘ë‹¨ì¼ìë¦¿ìˆ˜ ì„±ì¥). ì¡°ì • EBITDA ë§ˆì§„ ì•½ 300bp ì¶”ê°€ í™•ëŒ€ ëª©í‘œ. 1ë¶„ê¸°ëŠ” ì „ë…„ ëŒ€ë¹„ 1~2% ê°ì†Œ ì˜ˆìƒë˜ë‚˜ í•˜ë°˜ê¸° ê°€ì†í™” ì „ë§. ì‰ì—¬í˜„ê¸ˆíë¦„ì€ ì „ë…„ ëŒ€ë¹„ 30% ì´ìƒ ê°œ</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] Your first question comes from David Saxon with Needham.</td><td>**Operator:** [êµí™˜ì› ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ Needhamì˜ David Saxonë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Saxon: Needham & Company, LLC, Research Division Congrats on the quarter. So maybe I'll start with guidance. So 3% to 5% growth. I guess, what do you think the market is growing at, at this point? And then the decline in fiscal first quarter, down 1% to 2%, what's driving that across businesses, or even product categories? And then I think you'll lap the NIH funding dynamics in the fiscal first half. So would love to hear what's baked into guidance in terms of that impact. And then I'll have a follow-up.</td><td>**David Saxon:** ì¢‹ì€ ì‹¤ì  ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ë¨¼ì € ê°€ì´ë˜ìŠ¤ë¶€í„° ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 3%ì—ì„œ 5% ì„±ì¥ì„ ì œì‹œí•˜ì…¨ëŠ”ë°, í˜„ì¬ ì‹œì¥ì€ ì–´ëŠ ì •ë„ ì„±ì¥í•˜ê³  ìˆë‹¤ê³  ë³´ì‹œë‚˜ìš”? ê·¸ë¦¬ê³  íšŒê³„ì—°ë„ 1ë¶„ê¸° ë§¤ì¶œì´ 1%ì—ì„œ 2% ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì…¨ëŠ”ë°, ì‚¬ì—…ë¶€ë¬¸ë³„ë¡œ ë˜ëŠ” ì œí’ˆ ì¹´í…Œê³ ë¦¬ë³„ë¡œ ì–´ë–¤ ìš”ì¸ë“¤ì´ ì´ëŸ¬í•œ ê°ì†Œë¥¼ ì´ëŒê³  ìˆë‚˜ìš”? ê·¸ë¦¬ê³  íšŒê³„ì—°ë„ ìƒë°˜ê¸°ì— NIH í€ë”© ê´€ë ¨ ê¸°ì €íš¨ê³¼ê°€ í•´ì†Œë  ê²ƒìœ¼ë¡œ ë³´ì´ëŠ”ë°, ê°€ì´ë˜ìŠ¤ì— ê·¸ ì˜í–¥ì´ ì–´ë–»ê²Œ ë°˜ì˜ë˜ì–´ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì¶”ê°€ ì§ˆë¬¸ë„ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>John P. Marotta: President, CEO & Director Sure. You bet, David, good to be with you, and thank you for the questions. Let's talk about the macro and then I'll hand it over to Lawrence to get into the numbers. But a lot of what we're seeing is the slowdown on capital expenditures. That's continued to impact our stores in Cryo. And we're seeing some green shoots around that, particularly in the EU, and seeing less traction in the U.S. right now. There's some booking softness of course. The government shutdown from last month is really weighing on some of the guidance. The way to think about it is that midpoints for -- and that contemplates some deterioration in the macro on the low end. On the upper side, it's just a slow gradual improvement over the year. Regarding what we think the market is doing. We think the market is 1% to 2%. We're still an outgrowth story and that's kind of how our view of this is shaping up for '26. One thing to note is we're not focused on the first quarter, the first half. We're focused on delivering the year like we were this year, and that's really what the teams are laser focused on.</td><td>**John P. Marotta:** ë„¤, ë°ì´ë¹„ë“œ, ë°˜ê°‘ìŠµë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ê±°ì‹œê²½ì œ ìƒí™©ì— ëŒ€í•´ ë¨¼ì € ë§ì”€ë“œë¦¬ê³ , êµ¬ì²´ì ì¸ ìˆ˜ì¹˜ëŠ” ë¡œë ŒìŠ¤ê°€ ì„¤ëª…í•˜ê² ìŠµë‹ˆë‹¤. í˜„ì¬ ì €í¬ê°€ ëª©ê²©í•˜ê³  ìˆëŠ” ì£¼ìš” í˜„ìƒì€ ìë³¸ì§€ì¶œ(capital expenditures)ì˜ ë‘”í™”ì…ë‹ˆë‹¤. ì´ëŠ” ì €ì˜¨(Cryo) ë¶€ë¬¸ ë§¤ì¥ë“¤ì— ì§€ì†ì ìœ¼ë¡œ ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ìœ ëŸ½ì—ì„œëŠ” ì¼ë¶€ íšŒë³µ ì¡°ì§ì´ ë³´ì´ê³  ìˆì§€ë§Œ, ë¯¸êµ­ì—ì„œëŠ” ì•„ì§ ê·¸ ì •ë„ì˜ ê²¬ì¸ë ¥ì„ ë³´ì§€ ëª»í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ìˆ˜ì£¼ ì¸¡ë©´ì—ì„œë„ ë‹¤ì†Œ ë¶€ì§„í•¨ì´ ìˆìŠµë‹ˆë‹¤. ì§€ë‚œë‹¬ ì •ë¶€ ì…§ë‹¤ìš´ì´ ê°€ì´ë˜ìŠ¤ì— ìƒë‹¹í•œ ë¶€ë‹´ì„ ì£¼ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ê°€ì´ë˜ìŠ¤ë¥¼ ì´í•´í•˜ì‹œëŠ” ë°©ë²•ì€ ì´ë ‡ìŠµë‹ˆë‹¤. ì¤‘ê°„ê°’ ê¸°ì¤€ìœ¼ë¡œ ë³´ì‹œë©´ ë˜ê³ , í•˜ë‹¨ì€ ê±°ì‹œê²½ì œ ìƒí™©ì´ ë‹¤ì†Œ ì•…í™”ë˜ëŠ” ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ìƒë‹¨ì€ ì—°ì¤‘ ì™„ë§Œí•˜ê³  ì ì§„ì ì¸ ê°œì„ ì„ ê°€ì •í•œ ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì´ ì €í¬ê°€ ë³´ëŠ” ì‹œì¥ ìƒí™©ì…ë‹ˆë‹¤. ì‹œì¥ ì„±ì¥ë¥ ì€ 1~2% ì •ë„ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì—¬ì „íˆ ì‹œì¥ì„ ìƒíšŒí•˜ëŠ” ì„±ì¥ ìŠ¤í† ë¦¬ë¥¼ ì´ì–´ê°€ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ 26ë…„ì— ëŒ€í•œ ì €í¬ ê´€ì ì…ë‹ˆë‹¤. í•œ ê°€ì§€ ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€, ì €í¬ëŠ” 1ë¶„ê¸°ë‚˜ ìƒë°˜ê¸°ì— ì§‘ì¤‘í•˜ì§€ ì•ŠëŠ”ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì˜¬í•´ ê·¸ë¬ë˜ ê²ƒì²˜ëŸ¼ ì—°ê°„ ëª©í‘œ ë‹¬ì„±ì— ì§‘ì¤‘í•˜ê³  ìˆìœ¼ë©°, íŒ€ ì „ì²´ê°€ ì´ ë¶€ë¶„ì— ë ˆì´ì €ì²˜ëŸ¼ ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Lawrence Lin: Executive VP & CFO Yes, David, this is Lawrence. So let me give you a little color on 1Q. And really, John has touched on it a little bit, but a couple of things to inform our view, right? So the macro slowdown in the CapEx really will continue to impact our Automated Storage business in Cryo, right? As John mentioned, we are seeing some green shoots in Europe, but right now, not seeing much traction in the U.S. currently. The second is really the government shutdown, right? Overall, we were down about 45 days. John and I have heard from our customers that new grant reviews and approvals were paused during that time. And so it's going to take a bit of time to work through that through the system. So we don't expect this to impact the full year, obviously, but some of these bookings will push out to future quarters. As far as the proportion of the impact on the negative growth, I would say the macro slowdown on CapEx was about 2/3, and about 1/3 is related to government funding.</td><td>**Lawrence Lin:** ë„¤, David, ì €ëŠ” Lawrenceì…ë‹ˆë‹¤. 1ë¶„ê¸°ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Johnì´ ì´ë¯¸ ì¼ë¶€ ì–¸ê¸‰í–ˆì§€ë§Œ, ì €í¬ ì „ë§ì— ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ëª‡ ê°€ì§€ ìš”ì¸ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ë¨¼ì € ê±°ì‹œê²½ì œ ë‘”í™”ì™€ ìë³¸ì§€ì¶œ(CapEx) ê°ì†Œê°€ Cryo ë¶€ë¬¸ì˜ ìë™í™” ìŠ¤í† ë¦¬ì§€(Automated Storage) ì‚¬ì—…ì— ê³„ì† ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆìŠµë‹ˆë‹¤. Johnì´ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ìœ ëŸ½ì—ì„œëŠ” ì¼ë¶€ ê¸ì •ì ì¸ ì‹ í˜¸ë“¤ì´ ë³´ì´ê³  ìˆì§€ë§Œ, í˜„ì¬ ë¯¸êµ­ì—ì„œëŠ” ì•„ì§ í° ì§„ì „ì´ ì—†ëŠ” ìƒí™©ì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ëŠ” ì •ë¶€ ì…§ë‹¤ìš´ ë¬¸ì œì…ë‹ˆë‹¤. ì „ì²´ì ìœ¼ë¡œ ì•½ 45ì¼ ì •ë„ ì˜ì—…ì¼ì´ ì¤„ì–´ë“¤ì—ˆìŠµë‹ˆë‹¤. Johnê³¼ ì œê°€ ê³ ê°ë“¤ë¡œë¶€í„° ë“¤ì€ ë°”ë¡œëŠ” ê·¸ ê¸°ê°„ ë™ì•ˆ ì‹ ê·œ ì—°êµ¬ë¹„ ì‹¬ì‚¬ì™€ ìŠ¹ì¸ì´ ì¤‘ë‹¨ë˜ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ê²ƒì´ ì‹œìŠ¤í…œì„ í†µí•´ ì •ìƒí™”ë˜ê¸°ê¹Œì§€ëŠ” ë‹¤ì†Œ ì‹œê°„ì´ ê±¸ë¦´ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì—°ê°„ ì „ì²´ì—ëŠ” ì˜í–¥ì„ ë¯¸ì¹˜ì§€ ì•Šì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì§€ë§Œ, ì¼ë¶€ ìˆ˜ì£¼ëŠ” í–¥í›„ ë¶„ê¸°ë¡œ ì´ì—°ë  ê²ƒì…ë‹ˆë‹¤. ë§ˆì´ë„ˆìŠ¤ ì„±ì¥ì— ë¯¸ì¹œ ì˜í–¥ì˜ ë¹„ì¤‘ì„ ë§ì”€ë“œë¦¬ë©´, ê±°ì‹œê²½ì œ ë‘”í™”ë¡œ ì¸í•œ ìë³¸ì§€ì¶œ(CapEx) ê°ì†Œê°€ ì•½ 3ë¶„ì˜ 2, ì •ë¶€ ì˜ˆì‚° ê´€ë ¨ ìš”ì¸ì´ ì•½ 3ë¶„ì˜ 1 ì •ë„ë¼ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤.</td></tr>
<tr><td>David Saxon: Needham & Company, LLC, Research Division Okay. That's super helpful. And then the follow-up, I guess, is just on SMS growth for the year. So mid-single digits, you just talked about some weakness in stores in Cryo. So I guess, last quarter, you talked about the C&I backlog was like 2.5x annual sales. So maybe if you could -- can we get an update there? Like how much of that is driving your confidence in the mid-single-digit growth? And then how are you thinking about SRS for the year?</td><td>**David Saxon:** ë„¤, ì •ë§ ë„ì›€ì´ ë˜ëŠ” ë‹µë³€ì´ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í›„ì† ì§ˆë¬¸ì€ ì˜¬í•´ SMS ì„±ì¥ë¥ ì— ê´€í•œ ê²ƒì…ë‹ˆë‹¤. ì¤‘ë°˜ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°, ë°©ê¸ˆ Cryo ë§¤ì¥ì—ì„œì˜ ì•½ì„¸ì— ëŒ€í•´ ë§ì”€í•˜ì…¨ì–ì•„ìš”. ì§€ë‚œ ë¶„ê¸°ì— C&I ë°±ë¡œê·¸ê°€ ì—°ê°„ ë§¤ì¶œì˜ ì•½ 2.5ë°° ìˆ˜ì¤€ì´ë¼ê³  í•˜ì…¨ëŠ”ë°, í˜¹ì‹œ ê·¸ ë¶€ë¶„ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ë¥¼ ë°›ì„ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ê²Œ ì¤‘ë°˜ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì— ëŒ€í•œ í™•ì‹ ì„ ì£¼ëŠ” ìš”ì¸ì´ ì–¼ë§ˆë‚˜ ë˜ëŠ”ì§€ìš”? ê·¸ë¦¬ê³  ì˜¬í•´ SRSì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ì „ë§í•˜ê³  ê³„ì‹ ê°€ìš”?</td></tr>
<tr><td>Lawrence Lin: Executive VP & CFO Yes. Look, I think we've -- for C&I, we feel really good about kind of where we are. Some of the things that you'll see that inform why our SMS is mid-single digit is -- and John and I talked a bit about really reinvesting in commercial in fiscal 2025, we did that in GENEWIZ. What you're seeing in fiscal '26 is we've put in a commercial engine, new leadership. And right now, they're putting investments to work on feet on the street. That's one. So that's going to read through across all our SMS business lines. Now to talk a little bit about SRS. We expect robust growth in SRS, really through two things, right? You'll see that our commercial engine really starts to move. We just put a new leader in place. Additionally, there is -- and we talked a bit about this. We have an initiative in SRS, particularly to optimize our price. And that's going to read through starting in -- at the end of fiscal -- sorry, at the end of the first quarter. So those are two major components. And why we feel really good about SRS is really -- we've seen actually, recently, our commercial leaders close two meaningful big deals in the areas of manufactured and bulk compounds.</td><td>**Lawrence Lin:** ë„¤, ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. C&Iì˜ ê²½ìš° í˜„ì¬ ìƒí™©ì— ëŒ€í•´ ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. SMSê°€ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë³´ì´ëŠ” ì´ìœ ë¥¼ ì„¤ëª…ë“œë¦¬ìë©´ - ì¡´ê³¼ ì œê°€ ì´ì•¼ê¸°í–ˆë“¯ì´ 2025 íšŒê³„ì—°ë„ì— ìƒì—… ë¶€ë¬¸ì— ì¬íˆ¬ìë¥¼ ë‹¨í–‰í–ˆê³ , GENEWIZì—ì„œ ê·¸ë ‡ê²Œ í–ˆìŠµë‹ˆë‹¤. 2026 íšŒê³„ì—°ë„ì— ë³´ì‹œëŠ” ê²ƒì€ ìƒˆë¡œìš´ ìƒì—… ì—”ì§„ê³¼ ìƒˆë¡œìš´ ë¦¬ë”ì‹­ì„ êµ¬ì¶•í–ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. í˜„ì¬ í˜„ì¥ ì¸ë ¥ì— ëŒ€í•œ íˆ¬ìë¥¼ ì§‘í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì²« ë²ˆì§¸ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŠ” ëª¨ë“  SMS ì‚¬ì—… ë¶€ë¬¸ì— ê±¸ì³ ë°˜ì˜ë  ê²ƒì…ë‹ˆë‹¤. <br><br>ì´ì œ SRSì— ëŒ€í•´ ì¡°ê¸ˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. SRSì—ì„œëŠ” ë‘ ê°€ì§€ ìš”ì¸ì„ í†µí•´ ê²¬ê³ í•œ ì„±ì¥ì„ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìƒì—… ì—”ì§„ì´ ë³¸ê²©ì ìœ¼ë¡œ ê°€ë™ë˜ê¸° ì‹œì‘í•˜ëŠ” ê²ƒì„ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ë‹ˆë‹¤. ìƒˆë¡œìš´ ë¦¬ë”ë¥¼ ë§‰ ì„ëª…í–ˆìŠµë‹ˆë‹¤. ë˜í•œ - ì´ì— ëŒ€í•´ì„œëŠ” ì¡°ê¸ˆ ë§ì”€ë“œë ¸ëŠ”ë°ìš”. SRSì—ì„œ íŠ¹íˆ ê°€ê²© ìµœì í™”ë¥¼ ìœ„í•œ ì´ë‹ˆì…”í‹°ë¸Œë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” 1ë¶„ê¸° ë§ë¶€í„° ë³¸ê²©ì ìœ¼ë¡œ ë°˜ì˜ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ ë‘ ê°€ì§€ê°€ ì£¼ìš” ìš”ì†Œì…ë‹ˆë‹¤. <br><br>ê·¸ë¦¬ê³  SRSì— ëŒ€í•´ ì •ë§ ê¸ì •ì ìœ¼ë¡œ ë³´ëŠ” ì´ìœ ëŠ”, ìµœê·¼ ìš°ë¦¬ ì˜ì—… ë¦¬ë”ë“¤ì´ ì œì¡° í™”í•©ë¬¼ê³¼ ë²Œí¬ í™”í•©ë¬¼ ë¶„ì•¼ì—ì„œ ì˜ë¯¸ ìˆëŠ” ëŒ€í˜• ê³„ì•½ ë‘ ê±´ì„ ì„±ì‚¬ì‹œì¼°ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question comes from Mac Etoch with Stephens.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Stephensì˜ Mac Etochë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>John P. Marotta: President, CEO & Director Mac? We may be having an issue with Mac right now. Let's go to -- Mac, are you -- there we go. Yes Mac?</td><td>**John P. Marotta:** <budget:token_budget>199965</budget:token_budget><br><br>ì§€ê¸ˆ Macê³¼ ì—°ê²°ì— ë¬¸ì œê°€ ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë‹¤ë¥¸ ë¶„ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. Mac, ê³„ì‹œë‚˜ìš”? ë„¤, Mac ë§ì”€í•˜ì„¸ìš”.</td></tr>
<tr><td>Steven Etoch: Stephens Inc., Research Division Apologies. Sorry about that. You think I'd be able to find the mute button by now. As you highlighted, the macroeconomic backdrop is still a little bit challenged, specifically around capital equipment. But I'd love to just get an update on what you're seeing across your various customer bases at this point?</td><td>**Steven Etoch:** ì£„ì†¡í•©ë‹ˆë‹¤. ì´ì œì¯¤ì´ë©´ ìŒì†Œê±° ë²„íŠ¼ì„ ì°¾ì„ ìˆ˜ ìˆì„ ê²ƒ ê°™ì€ë° ë§ì´ì£ . ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ê±°ì‹œê²½ì œ í™˜ê²½ì´ ì—¬ì „íˆ ë‹¤ì†Œ ì–´ë ¤ìš´ ìƒí™©ì´ê³ , íŠ¹íˆ ìë³¸ì¬ ë¶€ë¬¸ì—ì„œ ê·¸ë ‡ìŠµë‹ˆë‹¤. í˜„ì¬ ì‹œì ì—ì„œ ì—¬ëŸ¬ ê³ ê° ê¸°ë°˜ì—ì„œ ì–´ë–¤ ìƒí™©ì„ ë³´ê³  ê³„ì‹ ì§€ ì—…ë°ì´íŠ¸ë¥¼ ë“£ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>John P. Marotta: President, CEO & Director Sure. We're seeing pharma. Of course, we're tapping into the profit pools of pharma and biotech right now. We're seeing strength in pharma. So there's spending going on there. There's some repositioning around projects in pharma right now with some of the restructuring that was going on, some of the projects were put on hold. We're seeing some of that get on stock at this point in time. So there's clarity around that. That means there's clarity with our Multiomics business in terms of what we're supporting from a testing perspective, from a synthesis perspective. We're seeing some investments and some clarity around optimization in biotech. Biotech is holding tight right now in terms of CapEx more so than pharma. And then we're seeing -- we were seeing a little bit more clarity in the academic and the government side, but that really -- that really started to slow down with this government shutdown. But all in all, it's more of a pharma story at this point in time.</td><td>**John P. Marotta:** ë¬¼ë¡ ì…ë‹ˆë‹¤. ì œì•½ ë¶€ë¬¸ì—ì„œ ê¸ì •ì ì¸ íë¦„ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ìš°ë¦¬ëŠ” ì œì•½ê³¼ ë°”ì´ì˜¤í…Œí¬ì˜ ìˆ˜ìµ í’€ì„ í™œìš©í•˜ê³  ìˆëŠ”ë°ìš”. ì œì•½ ë¶€ë¬¸ì—ì„œ ê°•ì„¸ë¥¼ ë³´ì´ê³  ìˆì–´ì„œ íˆ¬ì ì§‘í–‰ì´ ì´ë£¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì œì•½ ë¶€ë¬¸ì—ì„œ ì¼ë¶€ êµ¬ì¡°ì¡°ì •ì´ ì§„í–‰ë˜ë©´ì„œ í”„ë¡œì íŠ¸ ì¬í¸ì´ ìˆì—ˆê³ , ì¼ë¶€ í”„ë¡œì íŠ¸ë“¤ì´ ë³´ë¥˜ë˜ì—ˆë˜ ìƒí™©ì´ì—ˆìŠµë‹ˆë‹¤. í˜„ ì‹œì ì—ì„œëŠ” ì´ëŸ¬í•œ ë¶€ë¶„ë“¤ì´ ë‹¤ì‹œ ì›€ì§ì´ê¸° ì‹œì‘í•˜ëŠ” ê²ƒì„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ëª…í™•ì„±ì´ ìƒê²¼ë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. ìš°ë¦¬ ë©€í‹°ì˜¤ë¯¹ìŠ¤(Multiomics) ì‚¬ì—… ì¸¡ë©´ì—ì„œë„ í…ŒìŠ¤íŒ… ê´€ì , í•©ì„± ê´€ì ì—ì„œ ìš°ë¦¬ê°€ ì§€ì›í•˜ëŠ” ë¶€ë¶„ì— ëŒ€í•œ ëª…í™•ì„±ì´ ìƒê¸´ ê²ƒì´ì£ . ë°”ì´ì˜¤í…Œí¬ì—ì„œë„ ìµœì í™” ê´€ë ¨í•´ì„œ ì¼ë¶€ íˆ¬ìì™€ ëª…í™•ì„±ì„ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ë°”ì´ì˜¤í…Œí¬ëŠ” ì œì•½ì‚¬ë“¤ì— ë¹„í•´ ì„¤ë¹„íˆ¬ì(CapEx)ë¥¼ ì¢€ ë” ë³´ìˆ˜ì ìœ¼ë¡œ ì§‘í–‰í•˜ê³  ìˆëŠ” ìƒí™©ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  í•™ìˆ  ë° ì •ë¶€ ë¶€ë¬¸ì—ì„œëŠ” ì¡°ê¸ˆ ë” ëª…í™•í•œ ìƒí™©ì´ ë³´ì´ê³  ìˆì—ˆìŠµë‹ˆë‹¤ë§Œ, ì •ë¶€ ì…§ë‹¤ìš´ìœ¼ë¡œ ì¸í•´ ì‹¤ì œë¡œ ë‘”í™”ë˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì „ë°˜ì ìœ¼ë¡œ ë³´ë©´ í˜„ì¬ ì‹œì ì—ì„œëŠ” ì œì•½ ë¶€ë¬¸ì˜ ì´ì•¼ê¸°ë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Steven Etoch: Stephens Inc., Research Division I appreciate the color there. And then in terms of Multiomics, the low single-digit guide. I think that's -- I think, roughly in line with what people were expecting. But can you just parse out the various aspects that are contributing to that expectation for the year?</td><td>**Steven Etoch:** ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë©€í‹°ì˜¤ë¯¹ìŠ¤(Multiomics) ê´€ë ¨í•´ì„œ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥  ê°€ì´ë˜ìŠ¤ ë§ì”€ì´ì‹ ë°ìš”. ëŒ€ì²´ë¡œ ì‹œì¥ ì˜ˆìƒê³¼ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì¸ ê²ƒ ê°™ìŠµë‹ˆë‹¤ë§Œ, ì˜¬í•´ ì „ë§ì— ê¸°ì—¬í•˜ëŠ” ì—¬ëŸ¬ ìš”ì†Œë“¤ì„ ì¢€ ë” êµ¬ì²´ì ìœ¼ë¡œ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”?</td></tr>
<tr><td>John P. Marotta: President, CEO & Director Sure, you bet. More around the macro side, and I'll hand it over to Lawrence on the numbers. But on the macro, it's really this normalization on NGS. So past the technology curve, price normalization, volume normalization, those sorts of things. That's really what we're looking at from a Multiomics perspective. Why don't you give some color on the numbers?</td><td>**John P. Marotta:** ë„¤, ë¬¼ë¡ ì…ë‹ˆë‹¤. ê±°ì‹œì ì¸ ì¸¡ë©´ì—ì„œ ë¨¼ì € ë§ì”€ë“œë¦¬ê³ , êµ¬ì²´ì ì¸ ìˆ˜ì¹˜ëŠ” Lawrenceì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ê±°ì‹œì  ê´€ì ì—ì„œ ë³´ë©´, ì‹¤ì œë¡œ NGSì˜ ì •ìƒí™” ê³¼ì •ì…ë‹ˆë‹¤. ê¸°ìˆ  ê³¡ì„ ì„ ì§€ë‚˜ ê°€ê²© ì •ìƒí™”, ë¬¼ëŸ‰ ì •ìƒí™” ë“±ì´ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë©€í‹°ì˜¤ë¯¹ìŠ¤(Multiomics) ê´€ì ì—ì„œ ì €í¬ê°€ ë³´ê³  ìˆëŠ” ê²ƒì´ ë°”ë¡œ ì´ëŸ° ë¶€ë¶„ì…ë‹ˆë‹¤. Lawrence, ìˆ˜ì¹˜ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Lawrence Lin: Executive VP & CFO Yes. Look, Mac, first off, we are really pleased with our fourth quarter results for Multiomics. The team did a great job. Let's talk specifically a bit about Multiomics. A couple of things to note. And John alluded to this is, what you're going to see around Multiomics, in particular, NGS, is a bit of this normalization. So we expect NGS through the year to be roughly mid-single digits. As you may recall, we've kind of lapsed this price challenge in the prior year. We saw a lot of volume pick up. So seeing the double-digit number in fiscal 2025, you'll see that really kind of normalize back to mid-single-digit growth. Again, we feel really good about what the team has been doing particularly around the NGS space.</td><td>**Lawrence Lin:** ë„¤, ë§¥. ìš°ì„  4ë¶„ê¸° ë©€í‹°ì˜¤ë¯¹ìŠ¤ ì‹¤ì ì— ëŒ€í•´ ì •ë§ ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. íŒ€ì´ ì •ë§ í›Œë¥­í•œ ì„±ê³¼ë¥¼ ëƒˆìŠµë‹ˆë‹¤. ë©€í‹°ì˜¤ë¯¹ìŠ¤ì— ëŒ€í•´ êµ¬ì²´ì ìœ¼ë¡œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ëª‡ ê°€ì§€ ì£¼ëª©í•  ì ì´ ìˆëŠ”ë°ìš”. ì¡´ì´ ì–¸ê¸‰í–ˆë“¯ì´, ë©€í‹°ì˜¤ë¯¹ìŠ¤, íŠ¹íˆ NGSì—ì„œ ì •ìƒí™” í˜„ìƒì„ ë³´ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ì—°ì¤‘ NGS ì„±ì¥ë¥ ì€ ëŒ€ëµ ì¤‘ê°„ í•œìë¦¿ìˆ˜ ìˆ˜ì¤€ì´ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ê¸°ì–µí•˜ì‹œê² ì§€ë§Œ, ì „ë…„ë„ì— ê°€ê²© ë¬¸ì œë¥¼ ê·¹ë³µí–ˆê³  ë¬¼ëŸ‰ì´ í¬ê²Œ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ 2025 íšŒê³„ì—°ë„ì— ë‘ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë³´ì…¨ë‹¤ë©´, ì´ì œ ì¤‘ê°„ í•œìë¦¿ìˆ˜ ì„±ì¥ë¥ ë¡œ ì •ìƒí™”ë˜ëŠ” ëª¨ìŠµì„ ë³´ì‹œê²Œ ë  ê²ë‹ˆë‹¤. ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ì§€ë§Œ, íŠ¹íˆ NGS ë¶„ì•¼ì—ì„œ íŒ€ì´ í•´ì˜¨ ì¼ë“¤ì— ëŒ€í•´ ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ í‰ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question comes from Andrew Cooper with Raymond James.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Raymond Jamesì˜ Andrew Cooperë‹˜ê»˜ì„œ ì£¼ì‹­ë‹ˆë‹¤.</td></tr>
<tr><td>Andrew Cooper: Raymond James & Associates, Inc., Research Division Maybe first, a similar one to one that was just asked. But on the SMS side of the house in terms of that 3% to 5% growth, and maybe calling back -- or sorry, mid-single-digit growth, and then maybe calling back to the comment on optimizing price for fiscal '26. Can you give a little bit of a framework for how you think about each of the segments? And then how much is price contributing when we think about that mid-single-digit goal versus volume on an apples-to-apples basis?</td><td>**Andrew Cooper:** ë ˆì´ë¨¼ë“œ ì œì„ìŠ¤ ì•¤ ì–´ì†Œì‹œì—ì´ì¸ , ë¦¬ì„œì¹˜ ë¶€ë¬¸ ë¨¼ì € ë°©ê¸ˆ ì§ˆë¬¸ê³¼ ë¹„ìŠ·í•œ ë‚´ìš©ì¸ë°ìš”. SMS ë¶€ë¬¸ì˜ 3~5% ì„±ì¥, ì•„ë‹ˆ ì£„ì†¡í•©ë‹ˆë‹¤, ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì— ëŒ€í•´ì„œìš”. ê·¸ë¦¬ê³  26íšŒê³„ì—°ë„ ê°€ê²© ìµœì í™”ì— ëŒ€í•œ ë§ì”€ì„ ë‹¤ì‹œ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°ìš”. ê° ë¶€ë¬¸ì„ ì–´ë–»ê²Œ ë³´ê³  ê³„ì‹ ì§€ ì¡°ê¸ˆ ë” ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ì„±ì¥ ëª©í‘œë¥¼ ìƒê°í•  ë•Œ, ë™ì¼ ê¸°ì¤€ìœ¼ë¡œ ê°€ê²©ì´ ì–¼ë§ˆë‚˜ ê¸°ì—¬í•˜ê³  ë¬¼ëŸ‰ì´ ì–¼ë§ˆë‚˜ ê¸°ì—¬í•˜ëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>John P. Marotta: President, CEO & Director So just in terms of the portfolio durability with SRS specifically, I mean you're looking at contracts of 7 to 25 years, extremely stable, reoccurring revenue is in the 90% range in that part of our portfolio. And so we do have contractual obligations around price in particular. So a lot of strength in that. We really have not taken advantage of that in the past, and we're starting to do that now going forward in terms of sharing the value with our customers in terms of what we deliver. Lawrence, do you want to talk about the -- can you give some of the color on this?</td><td>**John P. Marotta:** ë¨¼ì € SRSì˜ í¬íŠ¸í´ë¦¬ì˜¤ ë‚´êµ¬ì„± ì¸¡ë©´ì—ì„œ ë§ì”€ë“œë¦¬ë©´, ê³„ì•½ ê¸°ê°„ì´ 7ë…„ì—ì„œ 25ë…„ì— ì´ë¥´ê³ , ë§¤ìš° ì•ˆì •ì ì´ë©°, í•´ë‹¹ í¬íŠ¸í´ë¦¬ì˜¤ ë¶€ë¬¸ì—ì„œ ë°˜ë³µ ë§¤ì¶œ(recurring revenue)ì´ 90% ìˆ˜ì¤€ì…ë‹ˆë‹¤. ë”°ë¼ì„œ íŠ¹íˆ ê°€ê²©ê³¼ ê´€ë ¨í•˜ì—¬ ê³„ì•½ìƒ ì˜ë¬´ì‚¬í•­ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì—ì„œ ìƒë‹¹í•œ ê°•ì ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê³¼ê±°ì—ëŠ” ì´ëŸ¬í•œ ê°•ì ì„ ì¶©ë¶„íˆ í™œìš©í•˜ì§€ ëª»í–ˆëŠ”ë°, ì´ì œëŠ” ê³ ê°ë“¤ì—ê²Œ ìš°ë¦¬ê°€ ì œê³µí•˜ëŠ” ê°€ì¹˜ë¥¼ ê³µìœ í•œë‹¤ëŠ” ì¸¡ë©´ì—ì„œ ì´ë¥¼ ì ê·¹ í™œìš©í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. Lawrence, ì´ ë¶€ë¶„ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Lawrence Lin: Executive VP & CFO Yes, absolutely. Let's start with SMS. Look, we've talked a bit about the slower start for the first quarter and first half on capital expenditures on stores in Cryo. We expect this to pick up in the second half of the year. When you look at C&I, the team continues to do well. As you probably know, we're specced into the workflows, right? There's a bit of the speed bump around the government shutdown, but overall, we expect to see this continue to be a very good business for us. Around SRS, again, John talked about a lot of the long-term contracts. We've got a new leader in place that's done a spectacular job. Like I mentioned earlier, we've won two pretty big deals in manufactured and compounds, and feel pretty good about kind of what we're seeing early on in fiscal '26. Now let's talk a little bit more on Multiomics. We touched on NGS. Gene Synthesis, we had -- we've seen some favorability coming out of the fourth quarter. We think this area is stabilizing nicely. And then on Sanger, look, this is still slow. We are seeing that Plasmid-EZ is offsetting that loss there. And I think that's going to be a trend that continues. I think you asked -- the other question was around price. Look, we've talked a bit -- a little bit about this kind of price optimization. Where we're seeing our ability to optimize on price is two areas. C&I, and then in SRS. And let me kind of double-click into SRS. One of the examples we're seeing historically in this business is we were constrained by our systems to deploy contracted, meaning it's built into our customers' contracts. We were not able to really deploy this effectively annually. The team has already done a good job and through the business system, streamline that process. Really, those are really the key areas that I referred to around price optimization.</td><td>**Lawrence Lin:** ë„¤, ë¬¼ë¡ ì…ë‹ˆë‹¤. SMSë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 1ë¶„ê¸°ì™€ ìƒë°˜ê¸°ì— ë§¤ì¥ê³¼ ê·¹ì €ì˜¨(Cryo) ë¶€ë¬¸ì˜ ìë³¸ì§€ì¶œ(capital expenditures)ì´ ë‹¤ì†Œ ë”ë””ê²Œ ì‹œì‘ëœ ë¶€ë¶„ì— ëŒ€í•´ ë§ì”€ë“œë¦° ë°” ìˆìŠµë‹ˆë‹¤. í•˜ë°˜ê¸°ì—ëŠ” ì´ ë¶€ë¶„ì´ íšŒë³µë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. C&I ë¶€ë¬¸ì„ ë³´ë©´, íŒ€ì´ ê³„ì†í•´ì„œ ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì•„ì‹œë‹¤ì‹œí”¼ ì €í¬ëŠ” ì›Œí¬í”Œë¡œìš°ì— ì‚¬ì–‘ìœ¼ë¡œ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì •ë¶€ ì…§ë‹¤ìš´ìœ¼ë¡œ ì¸í•œ ì•½ê°„ì˜ ì§€ì—°ì´ ìˆê¸´ í–ˆì§€ë§Œ, ì „ë°˜ì ìœ¼ë¡œ ì´ ì‚¬ì—…ì´ ì €í¬ì—ê²Œ ê³„ì†í•´ì„œ ë§¤ìš° ì¢‹ì€ ì‹¤ì ì„ ë‚¼ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. SRSì˜ ê²½ìš°, Johnì´ ë§ì€ ì¥ê¸° ê³„ì•½ë“¤ì— ëŒ€í•´ ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ìƒˆë¡œìš´ ë¦¬ë”ê°€ ë¶€ì„í•´ì„œ ì •ë§ í›Œë¥­í•œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì œì¡° ë° í™”í•©ë¬¼ ë¶„ì•¼ì—ì„œ ê½¤ í° ê·œëª¨ì˜ ê³„ì•½ ë‘ ê±´ì„ ìˆ˜ì£¼í–ˆê³ , 26íšŒê³„ì—°ë„ ì´ˆë°˜ì— ë³´ì´ëŠ” ìƒí™©ì— ëŒ€í•´ ìƒë‹¹íˆ ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ë©€í‹°ì˜¤ë¯¹ìŠ¤(Multiomics)ì— ëŒ€í•´ ì¢€ ë” ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. NGSì— ëŒ€í•´ì„œëŠ” ì–¸ê¸‰í–ˆê³ ìš”. ìœ ì „ì í•©ì„±(Gene Synthesis)ì˜ ê²½ìš°, 4ë¶„ê¸°ë¶€í„° ê¸ì •ì ì¸ íë¦„ì´ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶„ì•¼ê°€ ì•ˆì •í™”ë˜ê³  ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ìƒì–´ ì‹œí€€ì‹±(Sanger)ì˜ ê²½ìš°, ì—¬ì „íˆ ë”ë”˜ ìƒí™©ì…ë‹ˆë‹¤. ë‹¤ë§Œ Plasmid-EZê°€ ê·¸ ì†ì‹¤ì„ ìƒì‡„í•˜ê³  ìˆê³ , ì´ëŸ¬í•œ ì¶”ì„¸ëŠ” ê³„ì†ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ê°€ê²©ì— ëŒ€í•´ì„œë„ ì§ˆë¬¸í•˜ì‹  ê²ƒ ê°™ì€ë°ìš”. ê°€ê²© ìµœì í™”ì— ëŒ€í•´ ì¡°ê¸ˆ ë§ì”€ë“œë ¸ì—ˆëŠ”ë°, ê°€ê²© ìµœì í™”ê°€ ê°€ëŠ¥í•œ ì˜ì—­ì€ ë‘ ê³³ì…ë‹ˆë‹¤. C&Iì™€ SRSì…ë‹ˆë‹¤. SRSì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. <response><br><br>ì´ ì‚¬ì—…ì—ì„œ ì—­ì‚¬ì ìœ¼ë¡œ ë³´ì•„ì˜¨ ì‚¬ë¡€ ì¤‘ í•˜ë‚˜ëŠ”, ìš°ë¦¬ê°€ ì‹œìŠ¤í…œìƒì˜ ì œì•½ìœ¼ë¡œ ì¸í•´ ê³„ì•½ëœ ê°€ê²©, ì¦‰ ê³ ê° ê³„ì•½ì— í¬í•¨ëœ ê°€ê²©ì„ íš¨ê³¼ì ìœ¼ë¡œ ë§¤ë…„ ì ìš©í•˜ì§€ ëª»í–ˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. íŒ€ì—ì„œ ì´ë¯¸ í›Œë¥­í•œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìœ¼ë©°, ë¹„ì¦ˆë‹ˆìŠ¤ ì‹œìŠ¤í…œì„ í†µí•´ ê·¸ í”„ë¡œì„¸ìŠ¤ë¥¼ ê°„ì†Œí™”í–ˆìŠµë‹ˆë‹¤. ì œê°€ ë§ì”€ë“œë¦° ê°€ê²© ìµœì í™”(price optimization)ì™€ ê´€ë ¨ëœ í•µì‹¬ ì˜ì—­ë“¤ì´ ë°”ë¡œ ì´ëŸ° ë¶€ë¶„ë“¤ì…ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Andrew Cooper: Raymond James & Associates, Inc., Research Division Okay. Helpful. And then maybe one, John, you mentioned some of these moves to enable some of the different components of the business to make decisions closer to the customer. I guess maybe frame that relative to a history where I think there was some siloed aspects of operations that really needed to come together and get integrated a little bit more. So how do we balance those two sort of ideas and comments, and would love the framing of how they fit together in context of that 300 basis points of margin that I think is encouraging in a 3% to 5% top line environment?</td><td>**Andrew Cooper:** ì¢‹ì€ ì§ˆë¬¸ì…ë‹ˆë‹¤. ê³ ê°ê³¼ ë” ê°€ê¹Œìš´ ê³³ì—ì„œ ì˜ì‚¬ê²°ì •ì„ í•  ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ì¡°ì¹˜ë“¤ì— ëŒ€í•´ ë§ì”€ë“œë ¸ëŠ”ë°, ê³¼ê±°ì—ëŠ” ì‹¤ì œë¡œ í†µí•©ì´ í•„ìš”í–ˆë˜ ì‚¬ì¼ë¡œí™”ëœ ìš´ì˜ ì¸¡ë©´ë“¤ì´ ìˆì—ˆë˜ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ì´ ë‘ ê°€ì§€ ê°œë…ê³¼ ì˜ê²¬ë“¤ì„ ì–´ë–»ê²Œ ê· í˜•ìˆê²Œ ì¡°ìœ¨í•˜ëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§¤ì¶œ ì„±ì¥ë¥  3~5% í™˜ê²½ì—ì„œ 300bpì˜ ë§ˆì§„ ê°œì„ ì´ë¼ëŠ” ê³ ë¬´ì ì¸ ëª©í‘œì™€ ê´€ë ¨í•´ì„œ ì´ê²ƒë“¤ì´ ì–´ë–»ê²Œ ë§ë¬¼ë¦¬ëŠ”ì§€ ì„¤ëª…í•´ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>John P. Marotta: President, CEO & Director Of course, sure, sure. Happy to. So I think this is really important in terms of our go-to-market and how we're aligning the organization from a product line P&L perspective, and really having general managers and product managers aligned around these specific segments. We optimize and get synergies where it makes sense. And so we're moving from this very functionally aligned, central -- centrally aligned organization to a decentralized model. And you have that specifically built around, as I stated, around these product lines and these product managers. And so we've got general managers specifically in place now in all of the businesses. So that's kind of the first step in this. And there's clarity around that in the organization. And more importantly, it's putting R&D back into the businesses. Product management into the businesses. Sales and marketing back into the businesses. And then you have this regional go-to-market model where SRS, we've got a leader in SRS, but we also have specific leaders around better storage management. And we've got a clear expert that's leading that right now. We've got clarity around our go-to-market and who's leading that. All of those individuals are new in their roles. In C&I, and in stores in Cryo, very similar where we have a regional go-to-market model. The team is doing a great job by our European leader who is there now, and we just hired a new U.S. -- or North American leader as well, doing a great job. So out with customers all the time. The decision-making is at the point of impact regionally now. And so that's really -- it's really given the organization a lot of clarity. Similar to GENEWIZ and our Multiomics business, we moved to a regional go-to-market model. And it's working, and we're seeing a lot of green shoots around that specifically. So the point is, is there's more credibility, the closer you are to the customer, and we've really structured the organization around that. The synergies are around the systems, reporting systems, management information systems. We've really streamlined that. That makes a lot of sense to do that. But from an operating structure, we always talk about people structure process. Our structure is extremely nimble right now because it's very aligned around these product categories, where you've got clarity around your R&D road maps and those sorts of things, and then there's regional go-to-market model. So I appreciate the question. Thank you for that.</td><td>**John P. Marotta:** ë¬¼ë¡ ì´ì£ , ê¸°êº¼ì´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì€ ìš°ë¦¬ì˜ ì‹œì¥ ì§„ì¶œ ì „ëµê³¼ ì œí’ˆ ë¼ì¸ë³„ ì†ìµ(P&L) ê´€ì ì—ì„œ ì¡°ì§ì„ ì–´ë–»ê²Œ ì •ë ¬í•˜ëŠ”ì§€ì— ìˆì–´ ì •ë§ ì¤‘ìš”í•©ë‹ˆë‹¤. íŠ¹ì • ì„¸ê·¸ë¨¼íŠ¸ë¥¼ ì¤‘ì‹¬ìœ¼ë¡œ ì‚¬ì—…ë¶€ì¥ê³¼ ì œí’ˆ ê´€ë¦¬ìë“¤ì„ ì‹¤ì§ˆì ìœ¼ë¡œ ì—°ê³„ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. í•©ë¦¬ì ì¸ ë¶€ë¶„ì—ì„œëŠ” ìµœì í™”í•˜ê³  ì‹œë„ˆì§€ë¥¼ ì°½ì¶œí•˜ê³  ìˆê³ ìš”. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ë§¤ìš° ê¸°ëŠ¥ ì¤‘ì‹¬ì ì´ê³  ì¤‘ì•™ì§‘ì¤‘í™”ëœ ì¡°ì§ì—ì„œ ë¶„ê¶Œí™”ëœ ëª¨ë¸ë¡œ ì „í™˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼ ì´ëŸ¬í•œ ì œí’ˆ ë¼ì¸ê³¼ ì œí’ˆ ê´€ë¦¬ìë“¤ì„ ì¤‘ì‹¬ìœ¼ë¡œ êµ¬ì²´ì ìœ¼ë¡œ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ëª¨ë“  ì‚¬ì—…ë¶€ì— ì‚¬ì—…ë¶€ì¥ì„ ë°°ì¹˜í–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì²« ë²ˆì§¸ ë‹¨ê³„ë¼ê³  í•  ìˆ˜ ìˆì£ . ì¡°ì§ ë‚´ì—ì„œ ì´ì— ëŒ€í•œ ëª…í™•ì„±ì´ í™•ë³´ë˜ì—ˆìŠµë‹ˆë‹¤. ë” ì¤‘ìš”í•œ ê²ƒì€ R&Dë¥¼ ë‹¤ì‹œ ì‚¬ì—…ë¶€ë¡œ ëŒë ¤ë†“ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì œí’ˆ ê´€ë¦¬ë„ ì‚¬ì—…ë¶€ë¡œ, ì˜ì—…ê³¼ ë§ˆì¼€íŒ…ë„ ì‚¬ì—…ë¶€ë¡œ ëŒë ¤ë†“ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì§€ì—­ë³„ ì‹œì¥ ì§„ì¶œ ëª¨ë¸ì„ ìš´ì˜í•˜ê³  ìˆëŠ”ë°, SRSì˜ ê²½ìš° ë¦¬ë”ê°€ ìˆì§€ë§Œ ë” ë‚˜ì€ ì €ì¥ ê´€ë¦¬ë¥¼ ìœ„í•œ íŠ¹ì • ë¦¬ë”ë“¤ë„ ë°°ì¹˜í–ˆìŠµë‹ˆë‹¤. í˜„ì¬ ì´ ë¶„ì•¼ë¥¼ ì´ëŒê³  ìˆëŠ” ëª…í™•í•œ ì „ë¬¸ê°€ê°€ ìˆìŠµë‹ˆë‹¤. ì‹œì¥ ì§„ì¶œ ì „ëµê³¼ ì´ë¥¼ ì´ë„ëŠ” ë¦¬ë”ì‹­ë„ ëª…í™•í•©ë‹ˆë‹¤. ì´ ëª¨ë“  ì¸ë ¥ë“¤ì´ ìƒˆë¡œìš´ ì—­í• ì„ ë§¡ê³  ìˆìŠµë‹ˆë‹¤.<br><br>C&Iì™€ Cryoì˜ ì €ì¥ ì‚¬ì—…ë„ ë§¤ìš° ìœ ì‚¬í•œë°, ì§€ì—­ë³„ ì‹œì¥ ì§„ì¶œ ëª¨ë¸ì„ ìš´ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ìœ ëŸ½ ë¦¬ë”ê°€ í›Œë¥­í•˜ê²Œ íŒ€ì„ ì´ëŒê³  ìˆê³ , ìµœê·¼ì— ë¶ë¯¸ ë¦¬ë”ë„ ìƒˆë¡œ ì˜ì…í–ˆëŠ”ë° ì—­ì‹œ í›Œë¥­í•œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. í•­ìƒ ê³ ê°ë“¤ê³¼ í•¨ê»˜í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜ì‚¬ê²°ì •ì´ ì´ì œ ì§€ì—­ë³„ë¡œ í˜„ì¥ì—ì„œ ì´ë£¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì¡°ì§ì— ë§ì€ ëª…í™•ì„±ì´ ìƒê²¼ìŠµë‹ˆë‹¤. GENEWIZì™€ ë©€í‹°ì˜¤ë¯¹ìŠ¤(Multiomics) ì‚¬ì—…ê³¼ ë§ˆì°¬ê°€ì§€ë¡œ, ìš°ë¦¬ëŠ” ì§€ì—­ë³„ ì‹œì¥ì§„ì¶œ ëª¨ë¸ë¡œ ì „í™˜í–ˆìŠµë‹ˆë‹¤. ì´ ë°©ì‹ì´ íš¨ê³¼ë¥¼ ë³´ê³  ìˆê³ , íŠ¹íˆ ì´ ë¶€ë¶„ì—ì„œ ë§ì€ ê¸ì •ì ì¸ ì‹ í˜¸ë“¤ì´ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ìš”ì ì€ ê³ ê°ê³¼ ê°€ê¹Œìš¸ìˆ˜ë¡ ì‹ ë¢°ë„ê°€ ë†’ì•„ì§„ë‹¤ëŠ” ê²ƒì´ê³ , ìš°ë¦¬ëŠ” ì‹¤ì œë¡œ ê·¸ëŸ° ë°©í–¥ìœ¼ë¡œ ì¡°ì§ì„ êµ¬ì¡°í™”í–ˆìŠµë‹ˆë‹¤. ì‹œë„ˆì§€ëŠ” ì‹œìŠ¤í…œ, ë³´ê³  ì‹œìŠ¤í…œ, ê²½ì˜ì •ë³´ ì‹œìŠ¤í…œ ì¸¡ë©´ì—ì„œ ë‚˜ì˜¤ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì„ ì •ë§ íš¨ìœ¨í™”í–ˆê³ , ì´ë ‡ê²Œ í•˜ëŠ” ê²ƒì´ ë§¤ìš° í•©ë¦¬ì ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš´ì˜ êµ¬ì¡° ì¸¡ë©´ì—ì„œ ë³´ë©´, ìš°ë¦¬ëŠ” í•­ìƒ ì‚¬ëŒ, êµ¬ì¡°, í”„ë¡œì„¸ìŠ¤ì— ëŒ€í•´ ì´ì•¼ê¸°í•©ë‹ˆë‹¤. í˜„ì¬ ìš°ë¦¬ ì¡°ì§ êµ¬ì¡°ëŠ” ë§¤ìš° ê¸°ë¯¼í•˜ê²Œ ìš´ì˜ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì œí’ˆ ì¹´í…Œê³ ë¦¬ë¥¼ ì¤‘ì‹¬ìœ¼ë¡œ ì˜ ì •ë ¬ë˜ì–´ ìˆì–´ì„œ R&D ë¡œë“œë§µê³¼ ê°™ì€ ë¶€ë¶„ë“¤ì´ ëª…í™•í•˜ê³ , ì§€ì—­ë³„ ì‹œì¥ ì§„ì¶œ ëª¨ë¸ë„ í™•ë¦½ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì¢‹ì€ ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question comes from Vijay Kumar with Evercore ISI.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Evercore ISIì˜ Vijay Kumarë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Vijay Kumar: Evercore ISI Institutional Equities, Research Division Congrats on a nice print here. Maybe, John, on the macro comment that you're making on CapEx and the shutdown impact. We haven't heard that from some of your other life science tools peers. So curious on the trends that you're seeing, maybe just elaborate on that? And what are you assuming for the segments here in Q1 to get to the minus 1% to minus 2%?</td><td>**Vijay Kumar:** ì¢‹ì€ ì‹¤ì  ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. John, ì„¤ë¹„íˆ¬ìì™€ ì…§ë‹¤ìš´ ì˜í–¥ì— ëŒ€í•œ ê±°ì‹œì  ì½”ë©˜íŠ¸ ê´€ë ¨í•´ì„œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë‹¤ë¥¸ ìƒëª…ê³¼í•™ ë„êµ¬ ì—…ì²´ë“¤ë¡œë¶€í„°ëŠ” ê·¸ëŸ° ì–˜ê¸°ë¥¼ ë“£ì§€ ëª»í–ˆëŠ”ë°ìš”. í˜„ì¬ ë³´ê³  ê³„ì‹  íŠ¸ë Œë“œì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  1ë¶„ê¸°ì— ë§ˆì´ë„ˆìŠ¤ 1%ì—ì„œ ë§ˆì´ë„ˆìŠ¤ 2% ì „ë§ì¹˜ë¥¼ ì œì‹œí•˜ì…¨ëŠ”ë°, ê° ë¶€ë¬¸ë³„ë¡œ ì–´ë–¤ ê°€ì •ì„ í•˜ê³  ê³„ì‹ ì§€ìš”?</td></tr>
<tr><td>John P. Marotta: President, CEO & Director Sure. So we're seeing strength in the outsourcing trends, of course, because they want to outsource and partner with experts. And that's continuing. But where the pause in the softness was specifically around some projects with NIH and those sorts of entities that we do business with. People were just hitting the pause button right now through the government shutdown. We're starting to see kind of that being lapped, but this was an impact in the last 45 days. So a real impact to the organization. Mostly weaker in Multiomics. Lawrence, do you want to give some color on it?</td><td>**John P. Marotta:** ë¬¼ë¡ ì…ë‹ˆë‹¤. ì•„ì›ƒì†Œì‹± íŠ¸ë Œë“œëŠ” ì—¬ì „íˆ ê°•ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ê³ ê°ë“¤ì´ ì „ë¬¸ê°€ì™€ íŒŒíŠ¸ë„ˆì‹­ì„ ë§ºê³  ì•„ì›ƒì†Œì‹±í•˜ê¸°ë¥¼ ì›í•˜ê¸° ë•Œë¬¸ì´ì£ . ì´ëŸ° íë¦„ì€ ê³„ì†ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì¼ì‹œì ì¸ ë‘”í™”ê°€ ë°œìƒí•œ ë¶€ë¶„ì€ NIH ê°™ì€ ì •ë¶€ ê¸°ê´€ë“¤ê³¼ ì§„í–‰í•˜ë˜ ì¼ë¶€ í”„ë¡œì íŠ¸ì˜€ìŠµë‹ˆë‹¤. ì •ë¶€ ì…§ë‹¤ìš´ ê¸°ê°„ ë™ì•ˆ ì‚¬ëŒë“¤ì´ ê·¸ëƒ¥ ì¼ì‹œ ì¤‘ì§€ ë²„íŠ¼ì„ ëˆ„ë¥¸ ìƒí™©ì´ì—ˆì£ . ì´ì œ ê·¸ ì˜í–¥ì´ ì§€ë‚˜ê°€ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ë³´ì´ì§€ë§Œ, ì§€ë‚œ 45ì¼ê°„ì€ ì‹¤ì§ˆì ì¸ ì˜í–¥ì´ ìˆì—ˆìŠµë‹ˆë‹¤. ì¡°ì§ì— ì‹¤ì œë¡œ íƒ€ê²©ì„ ì¤€ ê²ƒì´ì£ . ì£¼ë¡œ ë©€í‹°ì˜¤ë¯¹ìŠ¤(Multiomics) ë¶€ë¬¸ì—ì„œ ì•½ì„¸ê°€ ë‘ë“œëŸ¬ì¡ŒìŠµë‹ˆë‹¤. Lawrence, ì´ ë¶€ë¶„ì— ëŒ€í•´ ì¢€ ë” ì„¤ëª…í•´ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Lawrence Lin: Executive VP & CFO Yes. Look, I think on the first quarter, kind of the CapEx and then around the government shutdown. You'll see on the CapEx, obviously, that's weaker from a negative growth perspective in SMS, right? And then around the government shutdown, it's lean, to John's point, more on the Multiomics segment. There's a little bit in our C&I. But again, really, we still see that the full year, we are super bullish about kind of where we're going to land. Normally, Vijay, we really don't guide quarterly. Our teams, John and I, are really focused on hitting the year. But -- and then we still kind of commit to that.</td><td>**Lawrence Lin:** ë„¤, 1ë¶„ê¸° ê´€ë ¨í•´ì„œ ìë³¸ì§€ì¶œ(CapEx)ê³¼ ì •ë¶€ ì…§ë‹¤ìš´ ì´ìŠˆì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìë³¸ì§€ì¶œ ì¸¡ë©´ì—ì„œ ë³´ì‹œë©´ SMS ë¶€ë¬¸ì—ì„œ ë§ˆì´ë„ˆìŠ¤ ì„±ì¥ ê´€ì ì—ì„œ ì•½ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì •ë¶€ ì…§ë‹¤ìš´ì˜ ê²½ìš°, ì¡´ì´ ì–¸ê¸‰í–ˆë“¯ì´ ë©€í‹°ì˜¤ë¯¹ìŠ¤(Multiomics) ë¶€ë¬¸ì— ë” í° ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆìŠµë‹ˆë‹¤. C&I ë¶€ë¬¸ì—ë„ ì¼ë¶€ ì˜í–¥ì´ ìˆê¸´ í•˜ì§€ë§Œìš”. ê·¸ë ‡ì§€ë§Œ ì—°ê°„ ì „ë§ì— ëŒ€í•´ì„œëŠ” ì—¬ì „íˆ ìš°ë¦¬ê°€ ëª©í‘œí•œ ì§€ì ì— ë„ë‹¬í•  ê²ƒì´ë¼ê³  ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¹„ì œì´, ë³´í†µ ì €í¬ëŠ” ë¶„ê¸°ë³„ ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. ì¡´ê³¼ ì €ë¥¼ í¬í•¨í•œ ì €í¬ íŒ€ì€ ì—°ê°„ ëª©í‘œ ë‹¬ì„±ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ ì•½ì†ì€ ì—¬ì „íˆ ìœ íš¨í•©ë‹ˆë‹¤.</td></tr>
<tr><td>John P. Marotta: President, CEO & Director Vijay, one other comment I would note. We went out -- recall when -- the beginning of the year, there was a lot of headwinds around government funding, NIH, in particular, some of the tariffs. We went out to over 100 customers and had a lot over 100 data points directly from them on what they were seeing. That gave us a lot of confidence around guiding in terms of this 1% headwind we were seeing in our business. And a lot of our peers at the time we're calling 20% issues around these headwinds, we were calling 1%. There was a little bit of a disbelief in that, but we felt confident because we had the data. We have the data right now around this, in particular, around VOC. I mean we are out with our customers. This regional go-to-market model allows us to get real-time data from our customers on what they're seeing in region, around specific programs in which we were supporting, and/or are supporting. So that gives us the clarity there regarding our point of view on it.</td><td>**John P. Marotta:** ì—°ì´ˆì— ì •ë¶€ ì˜ˆì‚°, íŠ¹íˆ NIH ì˜ˆì‚°ê³¼ ì¼ë¶€ ê´€ì„¸ ë¬¸ì œë¡œ ë§ì€ ì—­í’ì´ ìˆì—ˆë˜ ê²ƒì„ ê¸°ì–µí•˜ì‹¤ ê²ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 100ê°œ ì´ìƒì˜ ê³ ê°ì‚¬ë¥¼ ì§ì ‘ ë°©ë¬¸í•´ì„œ ê·¸ë“¤ì´ ì‹¤ì œë¡œ ê²½í—˜í•˜ê³  ìˆëŠ” ìƒí™©ì— ëŒ€í•œ 100ê°œ ì´ìƒì˜ ë°ì´í„° í¬ì¸íŠ¸ë¥¼ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ìš°ë¦¬ ì‚¬ì—…ì— 1%ì˜ ì—­í’ì´ ìˆë‹¤ëŠ” ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ëŠ” ë° í° í™•ì‹ ì„ ê°€ì§ˆ ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ë‹¹ì‹œ ë§ì€ ê²½ìŸì‚¬ë“¤ì´ ì´ëŸ¬í•œ ì—­í’ìœ¼ë¡œ ì¸í•´ 20%ì˜ ì˜í–¥ì„ ì˜ˆìƒí•˜ê³  ìˆì—ˆì§€ë§Œ, ìš°ë¦¬ëŠ” 1%ë¼ê³  ë§í–ˆìŠµë‹ˆë‹¤. ë‹¤ì†Œ ì˜êµ¬ì‹¬ì´ ìˆì—ˆë˜ ê²ƒë„ ì‚¬ì‹¤ì´ì§€ë§Œ, ìš°ë¦¬ëŠ” ë°ì´í„°ë¥¼ ê°€ì§€ê³  ìˆì—ˆê¸° ë•Œë¬¸ì— í™•ì‹ í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. ì§€ê¸ˆë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. íŠ¹íˆ VOCì™€ ê´€ë ¨í•´ì„œ ìš°ë¦¬ëŠ” ë°ì´í„°ë¥¼ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê³ ê°ë“¤ê³¼ ì§ì ‘ ì†Œí†µí•˜ê³  ìˆìŠµë‹ˆë‹¤. <response><br><br>ì´ëŸ¬í•œ ì§€ì—­ë³„ ì‹œì¥ ì§„ì¶œ ëª¨ë¸ì„ í†µí•´ ìš°ë¦¬ëŠ” ê³ ê°ë“¤ë¡œë¶€í„° ì‹¤ì‹œê°„ ë°ì´í„°ë¥¼ ë°›ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì§€ì—­ì—ì„œ ë¬´ì—‡ì„ ë³´ê³  ìˆëŠ”ì§€, ìš°ë¦¬ê°€ ì§€ì›í–ˆê±°ë‚˜ í˜„ì¬ ì§€ì›í•˜ê³  ìˆëŠ” íŠ¹ì • í”„ë¡œê·¸ë¨ë“¤ê³¼ ê´€ë ¨í•´ì„œ ë§ì´ì£ . ê·¸ë˜ì„œ ì´ë¥¼ í†µí•´ ìš°ë¦¬ì˜ ê´€ì ì— ëŒ€í•œ ëª…í™•ì„±ì„ í™•ë³´í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Vijay Kumar: Evercore ISI Institutional Equities, Research Division That's helpful, John. And maybe one related on, I guess Larry, on the phasing. Looks like back half needs to be 6% or 6%-plus. I guess that confidence in the back half acceleration, Larry, how are you thinking about EPS for the year? I know you gave the EBITDA margin expansion. How should we think about any below the line items, and what should EPS be?</td><td>**Vijay Kumar:** ë„ì›€ì´ ë˜ì…¨ë‹¤ë‹ˆ ë‹¤í–‰ì…ë‹ˆë‹¤, John. ê·¸ë¦¬ê³  ê´€ë ¨í•´ì„œ Larryê»˜ í•œ ê°€ì§€ ë” ì—¬ì­¤ë³´ê² ìŠµë‹ˆë‹¤. ì§„í–‰ ì†ë„ì— ê´€í•œ ê±´ë°ìš”. í•˜ë°˜ê¸°ì— 6% ë˜ëŠ” 6% ì´ìƒì˜ ì„±ì¥ì´ í•„ìš”í•´ ë³´ì…ë‹ˆë‹¤. í•˜ë°˜ê¸° ê°€ì†í™”ì— ëŒ€í•œ í™•ì‹ ê³¼ ê´€ë ¨í•´ì„œ, Larry, ì˜¬í•´ ì£¼ë‹¹ìˆœì´ìµ(EPS)ì€ ì–´ë–»ê²Œ ì „ë§í•˜ê³  ê³„ì‹ ê°€ìš”? EBITDA ë§ˆì§„ í™•ëŒ€ì— ëŒ€í•´ì„œëŠ” ë§ì”€í•´ ì£¼ì…¨ëŠ”ë°, ì˜ì—…ì™¸ í•­ëª©ë“¤ì€ ì–´ë–»ê²Œ ìƒê°í•´ì•¼ í• ê¹Œìš”? ê·¸ë¦¬ê³  EPSëŠ” ì–´ëŠ ì •ë„ê°€ ë ê¹Œìš”?</td></tr>
<tr><td>Lawrence Lin: Executive VP & CFO Yes. Look, I think if you look at how we're less than 50% of our full year revenue falls in the first half of the year. So generally, you're right. We feel really good about the second half of the year, Vijay. And why is that, right? We -- as we mentioned, we've really invested in feet on the street, particularly in SMS in starting this year. We put in almost 20 commercial heads and GENEWIZ earlier -- in mid fiscal 2025. On top of the price we talked about, that's all going to read through in the second half of the year. So we've got pretty good line of sight around that. In terms of EPS. Look, our EPS is going to be better, right? And so it's roughly -- it's roughly about $0.50 and [ 16 to 18 ] of other income similar to 2025.</td><td>**Lawrence Lin:** ë„¤, ë§ìŠµë‹ˆë‹¤. ì—°ê°„ ë§¤ì¶œì˜ 50% ë¯¸ë§Œì´ ìƒë°˜ê¸°ì— ë°œìƒí•˜ëŠ” êµ¬ì¡°ë¥¼ ë³´ì‹œë©´ ì•„ì‹œê² ì§€ë§Œ, ë§ì”€í•˜ì‹  ëŒ€ë¡œì…ë‹ˆë‹¤. Vijay, ì €í¬ëŠ” í•˜ë°˜ê¸°ì— ëŒ€í•´ ì •ë§ ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ ì´ìœ ë¥¼ ë§ì”€ë“œë¦¬ìë©´, ì•ì„œ ì–¸ê¸‰í–ˆë“¯ì´ ì˜¬í•´ ì´ˆë¶€í„° íŠ¹íˆ SMS ë¶€ë¬¸ì˜ í˜„ì¥ ì¸ë ¥ì— ìƒë‹¹í•œ íˆ¬ìë¥¼ ì§„í–‰í–ˆìŠµë‹ˆë‹¤. 2025 íšŒê³„ì—°ë„ ì¤‘ë°˜ì— GENEWIZì— ì•½ 20ëª…ì˜ ì˜ì—… ì±…ì„ìë¥¼ ë°°ì¹˜í–ˆê³ ìš”. ì´ë¯¸ ë§ì”€ë“œë¦° ê°€ê²© ì¸ìƒ íš¨ê³¼ì™€ ë”ë¶ˆì–´, ì´ ëª¨ë“  ê²ƒë“¤ì´ í•˜ë°˜ê¸°ì— ë³¸ê²©ì ìœ¼ë¡œ ë°˜ì˜ë  ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ë¶€ë¶„ì— ëŒ€í•´ì„œëŠ” ìƒë‹¹íˆ ëª…í™•í•œ ê°€ì‹œì„±ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì£¼ë‹¹ìˆœì´ìµ(EPS)ê³¼ ê´€ë ¨í•´ì„œëŠ”, ì‹¤ì ì´ ê°œì„ ë  ê²ƒì…ë‹ˆë‹¤. ëŒ€ëµ 0.50ë‹¬ëŸ¬ ì •ë„ì´ë©°, 2025ë…„ê³¼ ìœ ì‚¬í•˜ê²Œ 16~18ë‹¬ëŸ¬ì˜ ê¸°íƒ€ìˆ˜ìµì´ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>Vijay Kumar: Evercore ISI Institutional Equities, Research Division Sorry, if I may, one more, Larry. If margins are up 300 basis points, right? Is there some below-the-line impact? Like why is EPS flattish year-on-year?</td><td>**Vijay Kumar:** ì£„ì†¡í•œë°ìš”, ë˜ë¦¬, í•œ ê°€ì§€ë§Œ ë” ì—¬ì­¤ë³´ê² ìŠµë‹ˆë‹¤. ë§ˆì§„ì´ 300bp ìƒìŠ¹í•œë‹¤ë©´, ì˜ì—…ì™¸ í•­ëª©ì—ì„œ ì–´ë–¤ ì˜í–¥ì´ ìˆëŠ” ê±´ê°€ìš”? EPSê°€ ì „ë…„ ëŒ€ë¹„ ê±°ì˜ ë³€ë™ì´ ì—†ëŠ” ì´ìœ ê°€ ë­”ê°€ìš”?</td></tr>
<tr><td>Lawrence Lin: Executive VP & CFO Yes. So EPS is going to be greater than $0.50. So -- we -- I guess maybe clarify that. Really sure your question, Vijay.</td><td>**Lawrence Lin:** ë„¤, EPSëŠ” 0.50ë‹¬ëŸ¬ë¥¼ ìƒíšŒí•  ê²ƒì…ë‹ˆë‹¤. ì§ˆë¬¸ì„ ëª…í™•íˆ ì´í•´í–ˆëŠ”ì§€ í™•ì‹¤í•˜ì§€ ì•Šë„¤ìš”, Vijay.</td></tr>
<tr><td>John P. Marotta: President, CEO & Director Vijay, the way to think about -- the way to think about how we look at value here is if you pull back and take a look at the way we're looking at value right now, we're trading at 10x EBITDA, and we think we're undervalued right now. $12 of our stock is cash. And so we're focused around driving that margin expansion on the EBITDA line right now, and that's pretty important to us in terms of how we look at economic value. We do not typically guide on the EPS line, right?</td><td>**John P. Marotta:** í˜„ì¬ ìš°ë¦¬ê°€ ê°€ì¹˜ë¥¼ ì–´ë–»ê²Œ ë³´ê³  ìˆëŠ”ì§€ ë§ì”€ë“œë¦¬ìë©´, í•œ ë°œì§ ë¬¼ëŸ¬ì„œì„œ ë³´ë©´ ì§€ê¸ˆ ìš°ë¦¬ëŠ” EBITDAì˜ 10ë°°ì— ê±°ë˜ë˜ê³  ìˆê³ , ì €í¬ëŠ” í˜„ì¬ ì €í‰ê°€ë˜ì–´ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ìš°ë¦¬ ì£¼ê°€ì˜ 12ë‹¬ëŸ¬ëŠ” í˜„ê¸ˆì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ì§€ê¸ˆ EBITDA ë¼ì¸ì—ì„œ ë§ˆì§„ í™•ëŒ€ë¥¼ ì¶”ì§„í•˜ëŠ” ë° ì§‘ì¤‘í•˜ê³  ìˆìœ¼ë©°, ì´ê²ƒì´ ê²½ì œì  ê°€ì¹˜ë¥¼ ë°”ë¼ë³´ëŠ” ê´€ì ì—ì„œ ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤. ì €í¬ëŠ” ì¼ë°˜ì ìœ¼ë¡œ EPS ë¼ì¸ì— ëŒ€í•´ì„œëŠ” ê°€ì´ë˜ìŠ¤ë¥¼ ì œì‹œí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Lawrence Lin: Executive VP & CFO Yes. And so -- I mean, we expect it to be better than $0.50.</td><td>**Lawrence Lin:** ë„¤, ê·¸ë˜ì„œ ì €í¬ëŠ” 0.50ë‹¬ëŸ¬ë³´ë‹¤ëŠ” ë‚˜ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question comes from Brendan Smith with TD Cowen.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ TD Cowenì˜ Brendan Smith ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jacqueline Kisa: TD Cowen, Research Division This is Jacqueline on for Brendan. Congrats on the quarter. Maybe just doubling down on some of your expectations on timing for the potential M&A deals or tuck-ins over the year. What areas are you kind of looking to pursue in the near term? And how has the macro environment shifted your expectations on both when and where to acquire?</td><td>**Jacqueline Kisa:** ì‹¤ì  ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ì˜¬í•´ ì ì¬ì ì¸ M&A ê±°ë˜ë‚˜ ì†Œê·œëª¨ ì¸ìˆ˜ì— ëŒ€í•œ ì‹œê¸° ì „ë§ì„ ì¢€ ë” ìì„¸íˆ ì—¬ì­¤ë³´ê³  ì‹¶ìŠµë‹ˆë‹¤. ë‹¨ê¸°ì ìœ¼ë¡œ ì–´ë–¤ ë¶„ì•¼ë¥¼ ì¶”ì§„í•˜ì‹¤ ê³„íšì´ì‹ ê°€ìš”? ê·¸ë¦¬ê³  ê±°ì‹œê²½ì œ í™˜ê²½ì´ ì¸ìˆ˜ ì‹œê¸°ì™€ ëŒ€ìƒì— ëŒ€í•œ ê·€ì‚¬ì˜ ê¸°ëŒ€ì¹˜ë¥¼ ì–´ë–»ê²Œ ë³€í™”ì‹œì¼°ëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>John P. Marotta: President, CEO & Director Sure. Our focus around M&A has been pretty consistent, and that is on -- in regards specifically to tuck-ins and how we look at it. So just to reiterate on how we look at capital allocation. First is around growth opportunities in capital allocation. So what are we doing to support our growth initiatives from an R&D perspective, sales and marketing perspective, gross margin and productivity improvements. Third is around tuck-ins, in M&A. And fourth is around specifically share buyback. So parking on the M&A side, it's really expanding our core business. So the criteria around that is going to be specifically around SRS, expanding our scale in that space. We're really bullish about our targets there and what our M&A funnel looks like. Second is around our automated solutions and driving some M&A around C&I and stores specifically. And then third, around synthesis and how we're investing around synthesis. So I would think about those 3 areas in which we're looking at M&A. I would think about '26 as being our year of executing on that, specifically. '25 was really this reset, building a stable foundation to be able to absorb those type of acquisitions right now. So that's the focus in those areas specifically.</td><td>**John P. Marotta:** ì €í¬ì˜ M&A ì§‘ì¤‘ ì „ëµì€ ì¼ê´€ë˜ê²Œ ìœ ì§€ë˜ì–´ ì™”ìœ¼ë©°, íŠ¹íˆ ì†Œê·œëª¨ ì¸ìˆ˜í•©ë³‘(tuck-in)ì— ì´ˆì ì„ ë§ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ìë³¸ ë°°ë¶„ì— ëŒ€í•œ ì €í¬ ì ‘ê·¼ ë°©ì‹ì„ ë‹¤ì‹œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.<br><br>ì²«ì§¸ëŠ” ì„±ì¥ ê¸°íšŒë¥¼ ìœ„í•œ ìë³¸ ë°°ë¶„ì…ë‹ˆë‹¤. R&D ê´€ì , ì˜ì—… ë° ë§ˆì¼€íŒ… ê´€ì , ê·¸ë¦¬ê³  ë§¤ì¶œì´ì´ìµë¥ ê³¼ ìƒì‚°ì„± ê°œì„  ì¸¡ë©´ì—ì„œ ì„±ì¥ ì´ë‹ˆì…”í‹°ë¸Œë¥¼ ì§€ì›í•˜ê¸° ìœ„í•´ ë¬´ì—‡ì„ í•˜ê³  ìˆëŠ”ê°€ì…ë‹ˆë‹¤. ì…‹ì§¸ëŠ” ì†Œê·œëª¨ ì¸ìˆ˜í•©ë³‘ì…ë‹ˆë‹¤. ë„·ì§¸ëŠ” ìì‚¬ì£¼ ë§¤ì…ì…ë‹ˆë‹¤.<br><br>M&A ë¶€ë¶„ì— ì§‘ì¤‘í•´ì„œ ë§ì”€ë“œë¦¬ë©´, í•µì‹¬ ì‚¬ì—… í™•ì¥ì´ ëª©í‘œì…ë‹ˆë‹¤. ì´ì— ëŒ€í•œ ê¸°ì¤€ì€ êµ¬ì²´ì ìœ¼ë¡œ SRS ë¶€ë¬¸ì„ ì¤‘ì‹¬ìœ¼ë¡œ, í•´ë‹¹ ì˜ì—­ì—ì„œ ì €í¬ ê·œëª¨ë¥¼ í™•ëŒ€í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì €í¬ê°€ ëª©í‘œë¡œ í•˜ëŠ” ëŒ€ìƒ ê¸°ì—…ë“¤ê³¼ M&A íŒŒì´í”„ë¼ì¸ í˜„í™©ì— ëŒ€í•´ ë§¤ìš° ê¸ì •ì ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë‘ ë²ˆì§¸ëŠ” ìë™í™” ì†”ë£¨ì…˜ê³¼ ê´€ë ¨í•´ì„œ C&I(ìƒì—… ë° ì‚°ì—…) ë° ë§¤ì¥ ë¶€ë¬¸ì„ ì¤‘ì‹¬ìœ¼ë¡œ M&Aë¥¼ ì¶”ì§„í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì„¸ ë²ˆì§¸ëŠ” í•©ì„± ë¶€ë¬¸ê³¼ ì´ ë¶„ì•¼ì— ëŒ€í•œ íˆ¬ìì…ë‹ˆë‹¤. ì´ ì„¸ ê°€ì§€ ì˜ì—­ì´ ìš°ë¦¬ê°€ M&Aë¥¼ ê²€í† í•˜ê³  ìˆëŠ” ë¶„ì•¼ë¼ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤. 26ë…„ì„ ì´ëŸ¬í•œ M&A ì‹¤í–‰ì˜ í•´ë¡œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. 25ë…„ì€ ì‹¤ì§ˆì ìœ¼ë¡œ ì¬ì •ë¹„ì˜ ì‹œê¸°ì˜€ê³ , ì´ëŸ° ìœ í˜•ì˜ ì¸ìˆ˜ë¥¼ ì†Œí™”í•  ìˆ˜ ìˆëŠ” ì•ˆì •ì ì¸ ê¸°ë°˜ì„ êµ¬ì¶•í•˜ëŠ” ë° ì§‘ì¤‘í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ í˜„ì¬ ì´ëŸ¬í•œ íŠ¹ì • ì˜ì—­ë“¤ì— ì´ˆì ì„ ë§ì¶”ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jacqueline Kisa: TD Cowen, Research Division That's very helpful. And then maybe just one more. Double clicking on the Automated Stores, which seems to be on the upswing. How should we think about the near- and long-term expectations for both the performance and customer spend of that line? And how contributive do you expect it to be in the future for rev growth in that SMS segment?</td><td>**Jacqueline Kisa:** <response><br><br>ë§¤ìš° ë„ì›€ì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í•œ ê°€ì§€ë§Œ ë” ì—¬ì­™ê² ìŠµë‹ˆë‹¤. ìƒìŠ¹ì„¸ë¥¼ ë³´ì´ê³  ìˆëŠ” ìë™í™” ìŠ¤í† ì–´(Automated Stores)ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì‚´í´ë³´ê³  ì‹¶ì€ë°ìš”. í•´ë‹¹ ë¼ì¸ì˜ ì„±ê³¼ì™€ ê³ ê° ì§€ì¶œì— ëŒ€í•œ ë‹¨ê¸° ë° ì¥ê¸° ì „ë§ì„ ì–´ë–»ê²Œ ë´ì•¼ í• ê¹Œìš”? ê·¸ë¦¬ê³  í–¥í›„ SMS ë¶€ë¬¸ì˜ ë§¤ì¶œ ì„±ì¥ì— ì–¼ë§ˆë‚˜ ê¸°ì—¬í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œë‚˜ìš”?<br><br></response></td></tr>
<tr><td>John P. Marotta: President, CEO & Director Sure. Consistent with the past. I mean, when the macro starts to come back, I think you're going to see more strength in that segment. But we're also investing a lot in R&D in that segment in particular. And so that, we won't see that read through until '27, '28. We'll talk more about this in our long term -- in our long-range plan in Indianapolis in December, on our Investor Day. We'll get into the particulars of this, and we'll give you some more detail on it. But listen, we're investing behind this. We are not in the freezer business. We're in automated solutions business. And what that means is you have highly, highly complex electronics in a cold environment in some applications for our customers. That's Cryogenic. There's a lot of tailwinds around cryogenic cold storage because of cell and gene therapy and the moves being made there. I mean 50% of the therapeutics coming out, that are coming through FDA right now need ultra cold or cold. And so we feel like we're well positioned, and we're going to continue to position our product portfolio to enjoy those tailwinds. We'll get into that, of course, in Indianapolis.</td><td>**John P. Marotta:** ë„¤, ê³¼ê±°ì™€ ì¼ê´€ë˜ê²Œ ë§ì”€ë“œë¦¬ë©´, ê±°ì‹œê²½ì œê°€ íšŒë³µë˜ê¸° ì‹œì‘í•˜ë©´ í•´ë‹¹ ë¶€ë¬¸ì—ì„œ ë” ê°•í•œ ì„±ì¥ì„¸ë¥¼ ë³´ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” íŠ¹íˆ ì´ ë¶€ë¬¸ì— R&D íˆ¬ìë¥¼ ë§ì´ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ê·¸ ì„±ê³¼ëŠ” '27ë…„, '28ë…„ê¹Œì§€ëŠ” ë‚˜íƒ€ë‚˜ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤. ì´ì— ëŒ€í•´ì„œëŠ” 12ì›” ì¸ë””ì• ë‚˜í´ë¦¬ìŠ¤ì—ì„œ ì—´ë¦¬ëŠ” íˆ¬ììì˜ ë‚ (Investor Day)ì— ì¥ê¸° ê³„íšì„ ë°œí‘œí•  ë•Œ ë” ìì„¸íˆ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. êµ¬ì²´ì ì¸ ë‚´ìš©ì„ ë‹¤ë£¨ë©´ì„œ ë” ìƒì„¸í•œ ì •ë³´ë¥¼ ì œê³µí•´ë“œë¦´ ì˜ˆì •ì…ë‹ˆë‹¤.<br><br>ë¶„ëª…íˆ ë§ì”€ë“œë¦¬ë©´, ìš°ë¦¬ëŠ” ì´ ë¶„ì•¼ì— íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ëƒ‰ë™ ì‚¬ì—…ì„ í•˜ëŠ” ê²ƒì´ ì•„ë‹™ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìë™í™” ì†”ë£¨ì…˜ ì‚¬ì—…ì„ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì˜ë¯¸í•˜ëŠ” ë°”ëŠ”, ì¼ë¶€ ê³ ê° ì• í”Œë¦¬ì¼€ì´ì…˜ì—ì„œ ê·¹ì €ì˜¨ í™˜ê²½ì— ë§¤ìš° ë³µì¡í•œ ì „ìì¥ì¹˜ë¥¼ êµ¬í˜„í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ê²ƒì´ ë°”ë¡œ ê·¹ì €ì˜¨(Cryogenic) ì‚¬ì—…ì…ë‹ˆë‹¤. ì„¸í¬ ë° ìœ ì „ì ì¹˜ë£Œì œ ë¶„ì•¼ì˜ ë°œì „ìœ¼ë¡œ ê·¹ì €ì˜¨ ëƒ‰ë™ ë³´ê´€ì— ëŒ€í•œ ìˆ˜ìš”ê°€ í¬ê²Œ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ FDA ìŠ¹ì¸ ê³¼ì •ì„ ê±°ì¹˜ê³  ìˆëŠ” ì¹˜ë£Œì œì˜ 50%ê°€ ì´ˆì €ì˜¨ ë˜ëŠ” ëƒ‰ì¥ ë³´ê´€ì„ í•„ìš”ë¡œ í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ëŸ¬í•œ ì‹œì¥ íë¦„ì— ëŒ€ì‘í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆë‹¤ê³  íŒë‹¨í•˜ê³  ìˆìœ¼ë©°, ì´ëŸ¬í•œ ì„±ì¥ ê¸°íšŒë¥¼ í™œìš©í•  ìˆ˜ ìˆë„ë¡ ì œí’ˆ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì§€ì†ì ìœ¼ë¡œ ê°•í™”í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. ë¬¼ë¡  ì¸ë””ì• ë‚˜í´ë¦¬ìŠ¤ì—ì„œë„ ì´ ë¶€ë¶„ì„ ë³¸ê²©ì ìœ¼ë¡œ ì¶”ì§„í•  ì˜ˆì •ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Your next question comes from Paul Knight with KeyBanc.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ KeyBancì˜ Paul Knightë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Paul Knight: KeyBanc Capital Markets Inc., Research Division Congratulations on the quarter. And I'm kind of hopping on to that same topic of stores. So what do you think that market growth rate is? And I guess you're saying, too, that that's you're, probably, biggest area for rolling up that part of the marketplace. So what do you think market growth is, and relative to what are 10% biologic sales? Is that any kind of a proxy? And then again, is this the key M&A spot?</td><td>**Paul Knight:** ì¢‹ì€ ì‹¤ì  ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ì €ë„ ë§¤ì¥ ê´€ë ¨ ì£¼ì œë¥¼ ì´ì–´ê°€ê³ ì í•©ë‹ˆë‹¤. ì‹œì¥ ì„±ì¥ë¥ ì´ ì–´ëŠ ì •ë„ë¼ê³  ë³´ì‹œë‚˜ìš”? ê·¸ë¦¬ê³  ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼, ì´ ë¶€ë¶„ì´ ì‹œì¥ í†µí•©(roll-up)ì„ ìœ„í•œ ê°€ì¥ í° ì˜ì—­ì´ë¼ê³  í•˜ì…¨ëŠ”ë°ìš”. ì‹œì¥ ì„±ì¥ë¥ ì´ ì–´ëŠ ì •ë„ì´ê³ , 10% ìˆ˜ì¤€ì˜ ìƒë¬¼í•™ì  ì œí’ˆ ë§¤ì¶œê³¼ ë¹„êµí–ˆì„ ë•Œ ì–´ë–¤ ì—°ê´€ì„±ì´ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ë‹¤ì‹œ í•œ ë²ˆ ì—¬ì­™ìë©´, ì´ ë¶€ë¶„ì´ í•µì‹¬ M&A ëŒ€ìƒ ì˜ì—­ì¸ê°€ìš”?</td></tr>
<tr><td>John P. Marotta: President, CEO & Director Always an insightful question. So you basically kind of link the two, which is what -- the way we like to think about it from an automated solutions perspective. Stores in Cryo, we think, are low single digit right now. We're not in some of the veterinarian space that some of our peers are in Cryogenic. So we don't enjoy some of the vaccine tailwinds that are going on right now. What matters is, is when you've got an installed base that we have right now of hundreds of the Biological Stores, plus the attachment rate of our consumables which is increasing. I mean that business is really performing for us very nicely. And so you've got this attachment rate that's driving this data. The data output right now and the tools revolution is driving data. In our space, in our business, that is physical specimens, okay? And so we see that read through with the attachment rate of our consumables and sample tubes. And that's pretty important here. We've got a 100% attachment rate on the service side. And you've got -- we're driving more attachment rate on the C&I side. So to summarize, stores in Cryo, low single in our segment of the market, and we're still an outgrowth story based on us capturing market share, and then you've got these attachment rates on C&I. I will tell you -- I mean I'm so proud of our team and what they were able to deliver last year in a really tough macro. And we saw that across all of the segments of our business. And in some of the areas that were challenged, the team needed to pull back and work on some things operationally and we were able to do that. But we're also executing nicely on a lot of our attachment rates and installed base. C&I specifically, we have tens of thousands of instruments out there. And so our attachment rates, we're working on that specifically and you're seeing that read through as well. But it's a mixed story in terms of how we look at it. I hope that helps, Paul.</td><td>**John P. Marotta:** í•­ìƒ í†µì°°ë ¥ ìˆëŠ” ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë‘ ê°€ì§€ë¥¼ ì—°ê²°í•´ì„œ ì§ˆë¬¸í•˜ì…¨ëŠ”ë°, ìë™í™” ì†”ë£¨ì…˜ ê´€ì ì—ì„œ ì €í¬ë„ ê·¸ë ‡ê²Œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¹ì €ì˜¨(Cryo) ë¶„ì•¼ì˜ ìŠ¤í† ì–´ëŠ” í˜„ì¬ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì¼ë¶€ ê²½ìŸì‚¬ë“¤ì´ ì§„ì¶œí•´ ìˆëŠ” ê·¹ì €ì˜¨ ìˆ˜ì˜í•™ ë¶„ì•¼ì—ëŠ” ì•„ì§ ì§„ì…í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ í˜„ì¬ ì§„í–‰ ì¤‘ì¸ ë°±ì‹  ê´€ë ¨ ìˆ˜í˜œë¥¼ ëˆ„ë¦¬ì§€ëŠ” ëª»í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì¤‘ìš”í•œ ê²ƒì€, í˜„ì¬ ìˆ˜ë°± ëŒ€ì˜ ë°”ì´ì˜¬ë¡œì§€ì»¬ ìŠ¤í† ì–´(Biological Stores) ì„¤ì¹˜ ê¸°ë°˜ì„ ë³´ìœ í•˜ê³  ìˆê³ , ì†Œëª¨í’ˆ ë¶€ì°©ë¥ (attachment rate)ì´ ì¦ê°€í•˜ê³  ìˆë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì´ ì‚¬ì—…ì€ ì‹¤ì œë¡œ ë§¤ìš° ì¢‹ì€ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ë¶€ì°©ë¥ ì´ ë°ì´í„°ë¥¼ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ë°ì´í„° ì‚°ì¶œëŸ‰ê³¼ ë„êµ¬ í˜ëª…ì´ ë°ì´í„°ë¥¼ ì£¼ë„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ ë¶„ì•¼, ì €í¬ ì‚¬ì—…ì—ì„œëŠ” ë¬¼ë¦¬ì  ê²€ì²´ê°€ í•µì‹¬ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì†Œëª¨í’ˆê³¼ ìƒ˜í”Œ íŠœë¸Œì˜ ë¶€ì°©ë¥ (attachment rate)ì„ í†µí•´ ê·¸ íë¦„ì„ í™•ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ ë¶€ë¶„ì´ ìƒë‹¹íˆ ì¤‘ìš”í•œë°ìš”. ì„œë¹„ìŠ¤ ë¶€ë¬¸ì—ì„œëŠ” 100% ë¶€ì°©ë¥ ì„ ë‹¬ì„±í•˜ê³  ìˆê³ , C&I(ì†Œëª¨í’ˆ ë° ê¸°ê¸°) ë¶€ë¬¸ì—ì„œë„ ë¶€ì°©ë¥ ì„ ê³„ì† ë†’ì—¬ê°€ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì •ë¦¬í•˜ìë©´, ì €ì˜¨ ë³´ê´€(Cryo) ì‹œì¥ì˜ ì €í¬ ì„¸ê·¸ë¨¼íŠ¸ì—ì„œ ë§¤ì¥ ìˆ˜ëŠ” ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë³´ì´ê³  ìˆì§€ë§Œ, ì €í¬ëŠ” ì—¬ì „íˆ ì‹œì¥ ì ìœ ìœ¨ í™•ëŒ€ë¥¼ í†µí•œ ì´ˆê³¼ ì„±ì¥ ìŠ¤í† ë¦¬ë¥¼ ì´ì–´ê°€ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì— C&I ë¶€ë¬¸ì˜ ë¶€ì°©ë¥  ì¦ê°€ê°€ ë”í•´ì§€ëŠ” êµ¬ì¡°ì…ë‹ˆë‹¤.<br><br>ì •ë§ ì–´ë ¤ìš´ ê±°ì‹œê²½ì œ í™˜ê²½ ì†ì—ì„œë„ ì‘ë…„ì— ì €í¬ íŒ€ì´ ì´ë¤„ë‚¸ ì„±ê³¼ì— ëŒ€í•´ ë¬´ì²™ ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ê³¼ëŠ” ì €í¬ ì‚¬ì—…ì˜ ëª¨ë“  ë¶€ë¬¸ì—ì„œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì–´ë ¤ì›€ì„ ê²ªì—ˆë˜ ì¼ë¶€ ì˜ì—­ì—ì„œëŠ” íŒ€ì´ í•œ ë°œ ë¬¼ëŸ¬ë‚˜ì„œ ìš´ì˜ìƒì˜ ëª‡ ê°€ì§€ ì‚¬í•­ë“¤ì„ ê°œì„ í•´ì•¼ í–ˆê³ , ì €í¬ê°€ ê·¸ë ‡ê²Œ í•  ìˆ˜ ìˆì—ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë™ì‹œì— ë¶€ì°©ë¥ (attachment rate)ê³¼ ì„¤ì¹˜ ê¸°ë°˜(installed base) ì¸¡ë©´ì—ì„œë„ ìƒë‹¹íˆ ì˜ ì‹¤í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ C&Iì˜ ê²½ìš°, ìˆ˜ë§Œ ëŒ€ì˜ ì¥ë¹„ê°€ í˜„ì¥ì— ì„¤ì¹˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë¶€ì°©ë¥  ê°œì„ ì— ì§‘ì¤‘ì ìœ¼ë¡œ ë…¸ë ¥í•˜ê³  ìˆê³ , ê·¸ ì„±ê³¼ë„ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì „ì²´ì ìœ¼ë¡œ ë³´ë©´ ì—¬ëŸ¬ ìš”ì†Œê°€ í˜¼ì¬ëœ ìƒí™©ì´ë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë„ì›€ì´ ë˜ì…¨ê¸°ë¥¼ ë°”ëë‹ˆë‹¤, Paul.</td></tr>
<tr><td>Operator: There are no further questions at this time. I will now turn the call over to John for closing remarks.</td><td>**Operator:** í˜„ì¬ ë” ì´ìƒ ì§ˆë¬¸ì´ ì—†ìŠµë‹ˆë‹¤. ì´ì œ ë§ˆë¬´ë¦¬ ë°œì–¸ì„ ìœ„í•´ Johnì—ê²Œ ë„˜ê²¨ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>John P. Marotta: President, CEO & Director Excellent. Well, in summary, we entered '26 as a stronger company operationally and commercially and culturally. I want to thank again, our employees and our customers and our shareholders. We're excited about the road ahead, and we will certainly see you at Investor Day in December. Thank you again.</td><td>**John P. Marotta:** ìš”ì•½í•˜ìë©´, ìš°ë¦¬ëŠ” ìš´ì˜ì ìœ¼ë¡œë‚˜ ìƒì—…ì ìœ¼ë¡œ, ê·¸ë¦¬ê³  ì¡°ì§ë¬¸í™” ì¸¡ë©´ì—ì„œ ë”ìš± ê°•ë ¥í•œ íšŒì‚¬ë¡œ 2026ë…„ì„ ë§ì´í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ë‹¤ì‹œ í•œë²ˆ ìš°ë¦¬ ì„ì§ì›ë“¤ê³¼ ê³ ê° ì—¬ëŸ¬ë¶„, ê·¸ë¦¬ê³  ì£¼ì£¼ ì—¬ëŸ¬ë¶„ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì•ìœ¼ë¡œì˜ ì—¬ì •ì´ ë§¤ìš° ê¸°ëŒ€ë˜ë©°, 12ì›” íˆ¬ììì˜ ë‚ (Investor Day)ì—ì„œ ëµ™ê² ìŠµë‹ˆë‹¤. ë‹¤ì‹œ í•œë²ˆ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines.</td><td>**Operator:** ì‹ ì‚¬ ìˆ™ë…€ ì—¬ëŸ¬ë¶„, ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬ë“œë¦¬ë©°, ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Azenta ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>## ì£¼ìš” ì¬ë¬´ ì „ë§ ë° ì‹¤ì <br>- **FY26 ë§¤ì¶œ ê°€ì´ë˜ìŠ¤**: 3~5% ì„±ì¥ ì „ë§ (ì‹œì¥ ì„±ì¥ë¥  1~2% ëŒ€ë¹„ ì—¬ì „íˆ ì´ˆê³¼ ì„±ì¥)<br>- **1ë¶„ê¸° ì „ë§**: 1~2% ì—­ì„±ì¥ ì˜ˆìƒ - ìë³¸ ì§€ì¶œ ë‘”í™”ì™€ ì •ë¶€ ì…§ë‹¤ìš´(45ì¼ê°„) ì˜í–¥ìœ¼ë¡œ ì£¼ë¬¸ ì§€ì—° ë°œìƒ<br>- **EBITDA ë§ˆì§„**: 300bp ê°œì„  ëª©í‘œ, EPSëŠ” $0.50 ì´ìƒ ì˜ˆìƒ<br>- **ì„¸ê·¸ë¨¼íŠ¸ë³„ ì„±ì¥ë¥ **: SMS ì¤‘ê°„ ë‹¨ì¼ ìë¦¿ìˆ˜ ì„±ì¥, Multiomics ë‚®ì€ ë‹¨ì¼ ìë¦¿ìˆ˜ ì„±ì¥ (NGSëŠ” ì¤‘ê°„ ë‹¨ì¼ ìë¦¿ìˆ˜ë¡œ ì •ìƒí™”)<br><br>## ê²½ì˜ì§„ í†¤ ë° ì „ëµ<br>- **ê¸ì •ì  ìš”ì†Œ**: ìœ ëŸ½ì—ì„œ ì¼ë¶€ íšŒë³µ ì‹ í˜¸ ê°ì§€, ì œì•½ ë¶€ë¬¸ ì§€ì¶œ ê°•ì„¸, SRSì—ì„œ ëŒ€í˜• ê³„ì•½ 2ê±´ ì²´ê²°<br>- **ì¡°ì§ ì¬í¸**: ì œí’ˆ ë¼ì¸ë³„ P&L ì¤‘ì‹¬ì˜ ë¶„ê¶Œí™”ëœ ì§€ì—­ ì˜ì—… ëª¨ë¸ë¡œ ì „í™˜, ê³ ê° ë°€ì°©í˜• ì˜ì‚¬ê²°ì • êµ¬ì¡° êµ¬ì¶•<br>- **íˆ¬ì ìš°ì„ ìˆœìœ„**: 1) ì„±ì¥ ì´ë‹ˆì…”í‹°ë¸Œ 2) R&D/ì˜ì—… íˆ¬ì 3) M&A(SRS, ìë™í™” ì†”ë£¨ì…˜, í•©ì„± ë¶„ì•¼ ì§‘ì¤‘) 4) ìì‚¬ì£¼ ë§¤ì…<br><br>## ë¦¬ìŠ¤í¬ ë° ê°•ì <br>- **ë¦¬ìŠ¤í¬**: ë¯¸êµ­ ë‚´ ìë³¸ ì§€ì¶œ íšŒë³µ ì§€ì—°, ì •ë¶€</p>
    <hr style="margin:50px 0;">
    
</body></html>